

Europäische Patentamt  
European Patent Office  
Office européen des brevets



(11) **EP 0 892 058 A2**

(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:  
20.01.1999 Bulletin 1999/03

(51) Int. Cl.<sup>6</sup>: **C12N 15/54**, C12N 9/12,  
C12Q 1/68

(21) Application number: **98112327.6**

(22) Date of filing: **03.07.1998**

(84) Designated Contracting States:  
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE**  
Designated Extension States:  
**AL LT LV MK RO SI**

(72) Inventors:  
• Gelfand, David, Harrow  
Oakland, CA 94611 (US)  
• Reichert, Fred, Lawrence  
Oakland, CA 94610 (US)

(30) Priority: **09.07.1997 US 52065 P**

(74) Representative:  
**Wächter, Dieter Ernst, Dr. et al  
F.Hoffmann-La Roche AG  
Patent Department (PLP),  
124 Grenzacherstrasse  
4070 Basel (CH)**

(71) Applicant:  
**F. HOFFMANN-LA ROCHE AG  
4070 Basel (CH)**

(54) **Mutant chimeric DNA polymerases**

(57) The invention provides mutant, chimeric thermostable DNA polymerase enzymes, which chimeric thermostable DNA polymerase enzymes consist of an N-terminal region derived from the 5'-nuclease domain of a *Thermus* species DNA polymerase and a C-terminal region derived from the 3' to 5' exonuclease and polymerase domains of *Tma* DNA polymerase. These mutant chimeric thermostable DNA polymerase enzymes have improved properties in nucleic acid sequencing reactions. Also provided are nucleic acids encoding said mutant chimeric thermostable DNA polymerase enzymes, vectors comprising said nucleic acids and host cells transformed with said vectors. Also provided are compositions comprising said mutated, chimeric thermostable DNA polymerase enzymes and non-ionic polymeric detergent(s). Furthermore methods for producing the said enzymes and methods and kits for using the said enzymes are provided.

**EP 0 892 058 A2**

## Description

### Field of the Invention

The present invention relates to a mutant chimeric thermostable DNA polymerases, methods for their synthesis, and methods for their use. The enzymes are useful in many recombinant DNA techniques, especially in nucleic acid sequencing and in nucleic acid amplification by the polymerase chain reaction (PCR).

### Background Art

Thermostable DNA polymerases, which catalyze the template-directed polymerization of deoxyribonucleoside triphosphates (dNTPs) to form DNA, are used in a variety of in vitro DNA synthesis applications, such as DNA sequencing and DNA amplification. Typically, naturally occurring DNA polymerases strongly discriminate against the incorporation of nucleotide analogues. This property contributes to the fidelity of DNA replication and repair. However, the incorporation of nucleotide analogues is useful for many DNA synthesis applications, in particular, in DNA sequencing.

DNA sequencing reactions using the chain termination method initially described by Sanger *et al.*, 1977, *Proc. Natl. Acad. Sci.* 74:5463-5467, incorporated herein by reference, rely on an unconventional substrate, dideoxynucleoside triphosphate (ddNTP), for termination of synthesis. In the chain termination method, both the DNA polymerase's conventional substrate (dNTP) and a chain-terminating, unconventional substrate (ddNTP or labeled ddNTP) are present in the reaction. Synthesis proceeds until a ddNTP is incorporated. To insure that the chain-terminating ddNTPs are incorporated at a suitable rate, the inherent discrimination of the previously utilized DNA polymerases against the incorporation of ddNTPs was overcome by providing an excess of ddNTP.

Dye-terminator sequencing, a variant of the chain termination method, uses ddNTPs labeled with fluorescent dyes, such as fluorescein or rhodamine, to terminate synthesis and, simultaneously, to label the synthesized DNA. The presence of a dye label on the ddNTP can exacerbate the discrimination by the DNA polymerase against the incorporation of the unconventional substrate.

Typically, sequencing by the chain termination method is carried out using repeated steps of primer extension followed by heat denaturation of the primer extension product-template duplex. This embodiment, referred to as cycle sequencing, is carried out in a thermal cycler using a thermostable DNA polymerase. Kits for carrying out cycle sequencing are commercially available from, for example, Perkin Elmer, Norwalk, CT.

Thermostable DNA polymerases derived from a variety of organisms have been described extensively in the literature and are well known to one of skill in the art. Particular examples include DNA polymerases from a variety of species of the genus *Thermus* (see U.S. Patent No. 5,466,591), in particular from *Thermus aquaticus* (*Taq* DNA polymerase) described in U.S. Patent Nos. 4,889,818; 5,352,600; and 5,079,352; and the DNA polymerase from *Thermotoga maritima* (*Tma* DNA polymerase) described in U.S. Patent Nos. 5,374,553 and 5,420,029; all of which are incorporated herein by reference.

DNA polymerases typically possess one or more associated exonucleolytic activities. For example *Tma* DNA polymerase catalyzes the exonucleolytic removal of nucleotides from the 5'-end of a double-stranded DNA (referred to as 5' to 3' exonuclease activity or 5'-nuclease activity) as well as from the 3'-end of a single- or double-stranded DNA (referred to as 3' to 5' exonuclease activity). In contrast, DNA polymerases from the genus *Thermus* possess only 5'-nuclease activity. A review of thermostable DNA polymerases and their associated activities is found in Abramson, 1995, in PCR Strategies, (Innis *et al.* ed., Academic Press, Inc.). For use in DNA sequencing, a DNA polymerase that lacks associated exonucleolytic activity, either 5'-nuclease activity or 3' to 5' exonuclease activity, is preferred. Mutant forms of a number of thermostable DNA polymerases which lack 5'-nuclease activity are described in U.S. Patent No. 5,466,591, incorporated herein by reference.

European Patent Application 0 655 506, incorporated herein by reference, describes a mutated DNA polymerase with an enhanced ability to incorporate dideoxynucleotides (see also U.S. Patent No. 5,614,365, incorporated herein by reference). The mutation is a point mutation corresponding to amino acid 526 of T7 DNA polymerase. Examples of such mutations include mutations in amino acid 667 of *Taq* DNA polymerase.

AmpliTaq<sup>®</sup> DNA polymerase FS, a mutant form of *Taq* DNA polymerase that has essentially no 5'-nuclease activity and incorporates an F667Y mutation, is sold as a component of DNA cycle sequencing kits by Perkin Elmer, Norwalk, CT. The F667Y mutation results in a significant reduction in the discrimination against ddNTPs. This property greatly improves the sequencing data obtained from a dye-terminator sequencing reaction and reduces the amount of ddNTPs required for each sequencing reaction. However, the use of AmpliTaq<sup>®</sup> DNA polymerase, FS has not eliminated problems with non-uniformity of peak heights in the sequencing trace when used with the standard rhodamine dye family-labeled ddNTPs. An analysis of the peak height patterns obtained using AmpliTaq<sup>®</sup> DNA polymerase, FS in dye-terminator cycle sequencing reactions is described in Parker *et al.*, 1996, BioTechniques 21(4):694-699, incorporated herein by reference.

Conventional techniques of molecular biology and nucleic acid chemistry, which are within the skill of the art, are explained fully in the literature. See, for example, Sambrook *et al.*, 1989, Molecular Cloning - A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York; Oligonucleotide Synthesis (M.J. Gait, ed., 1984); Nucleic Acid Hybridization (B.D. Hames and S.J. Higgins, eds., 1984); and a series, Methods in Enzymology (Academic Press, Inc.), all of which are incorporated herein by reference. All patents, patent applications, and publications cited herein, both *supra* and *infra*, are incorporated herein by reference.

### Summary of the Invention

The present invention relates to mutant, chimeric thermostable DNA polymerases that possess significantly improved properties relative to previously described thermostable DNA polymerases. The DNA polymerase yields substantial improvements when used in DNA sequencing reactions. In particular, the DNA polymerase of the invention provides the following combination of advantageous properties:

- improved incorporation of ddNTPs;
- improved uniformity of peak heights in DNA sequencing traces, in particular when used with dye-labeled ddNTPs in a cycle sequencing reaction;
- reduced rate of pyrophosphorolysis of dye-labeled ddNTPs; and
- improved incorporation of dITP.

Furthermore, the DNA polymerase can be easily and efficiently expressed to a high level in a recombinant expression system, thereby facilitating commercial production of the enzyme. The combination of properties possessed by the DNA polymerase of the present invention represent a significant advantage over thermostable DNA polymerases previously described in the literature.

The chimeric DNA polymerases of the present invention consist of an N-terminal region derived from the 5'-nuclease domain of a *Thermus* species DNA polymerase and a C-terminal region derived from the 3' to 5' exonuclease and polymerase domains of *Tma* DNA polymerase. The N-terminal region contains at least a region of the *Thermus* species DNA polymerase corresponding to amino acids 1-38 of *Tma* DNA polymerase and may contain up to the entire 5'-nuclease domain of the *Thermus* species DNA polymerase. The C-terminal region contains, in addition to the 3' to 5'-exonuclease and polymerase domains of *Tma* DNA polymerase, a portion of the 5'-nuclease domain of *Tma* DNA polymerase corresponding to the portion of the 5'-nuclease domain of *Thermus* species DNA polymerase not present in the N-terminal region.

Thus, the chimeric DNA polymerase of the present invention consists of an N-terminal region and a C-terminal region, wherein said N-terminal region consists of amino acids 1 through n of a *Thermus* species DNA polymerase, wherein n is an amino acid position within a region of the *Thermus* species DNA polymerase corresponding to amino acids 138-291 of *Tma* DNA polymerase, and wherein said C-terminal region consists of amino acids m+1 through 893 of *Tma* DNA polymerase, wherein amino acid m in *Tma* DNA polymerase corresponds to amino acid n in the *Thermus* species DNA polymerase when *Tma* DNA polymerase and the *Thermus* species DNA polymerase are aligned as in the figures.

The chimeric DNA polymerase of the present invention is modified by a F730Y mutation in the DNA polymerase domain derived from *Tma* DNA polymerase, which increases the ability of the DNA polymerase to incorporate dideoxynucleotides.

In one embodiment, the 5'-nuclease domain of the chimeric DNA polymerase contains at least one point mutation that substantially reduces or, preferably, inactivates the 5'-nuclease activity. The mutation can be present either in the N-terminal, which is derived from the 5'-nuclease domain of the *Thermus* species DNA polymerase, or the portion of the C-terminal region that is derived from 5'-nuclease domain of *Tma* DNA polymerase, if present. Suitable mutations are those point mutations (single amino acid substitution or deletion mutations) that substantially reduce or, preferably, inactivate the 5'-nuclease activity in the source DNA polymerase. Thus, either the N-terminal region is modified by at least one amino acid substitution or deletion that substantially reduces or eliminates 5'-nuclease activity in the *Thermus* species DNA polymerase, or said C-terminal region is modified by at least one amino acid substitution or deletion within the region that is amino acids m+1 to 291 of *Tma* DNA polymerase that substantially reduces or eliminates 5'-nuclease activity in *Tma* DNA polymerase.

Amino acid positions which are critical to the 5'-nuclease activity of a DNA polymerase are well known, as described herein. A substitution of an amino acid at one or more of these critical positions or a deletion of an amino acid at one or more of these critical positions typically results in a decrease in the 5'-nuclease activity. Preferably, the chimeric DNA polymerase contains a mutation that substantially reduces or inactivates the 5'-nuclease activity.

In one embodiment, the C-terminal region, which contains the 3' to 5'- exonuclease domain derived from *Tma* DNA polymerase, contains at least one point mutation that substantially reduces or, preferably, inactivates the 3' to 5'

exonuclease activity in *Tma* DNA polymerase.

Amino acid positions which are critical to the 3' to 5' exonuclease activity of a DNA polymerase are well known, as described herein. A substitution of an amino acid at one or more of these critical positions or a deletion of an amino acid at one or more of these critical positions typically results in a decrease in the 3' to 5'-nuclease activity. In a preferred embodiment, the C-terminal region contains a D323A and a E325A mutation, which inactivate the 3' to 5, exonuclease activity.

In one embodiment, the N-terminal region is derived from *Taq* DNA polymerase. In a preferred embodiment, the N-terminal region consists of amino acids 1-190 of *Taq* DNA polymerase, and the C-terminal region consists of amino acids 191-893 of *Tma* DNA polymerase. In a particular preferred embodiment, designated F730Y *Tma*30 DNA Polymerase, the N-terminal region consists of amino acids 1-190 of *Taq* DNA polymerase and contains a G46D mutation, and the C-terminal region consists of amino acids 191-893 of *Tma* DNA polymerase and contains D323A, E325A, and F730Y mutations.

Another aspect of the present invention relates to the purified DNA (chimeric gene) which encodes the mutant, chimeric thermostable DNA polymerase of the invention, recombinant DNA vectors which contain the DNA, and host cells transformed with the recombinant DNA vectors. DNA sequences which differ only by silent nucleotide changes (i.e., which encode the same amino acid sequence) are within the intended scope of the invention.

In a preferred embodiment of the invention, the purified DNA consists of nucleotides 1-570 of a gene encoding *Taq* DNA polymerase modified to encode the G46D mutation, and nucleotides 571-2679 of a gene encoding *Tma* DNA polymerase modified to encode the D323A, E325A, and F730Y mutations.

Another aspect of the invention relates to methods for preparing the mutant, chimeric thermostable DNA polymerase of the invention using the purified DNA of the present invention. A recombinant expression vector is expressed in a host cell, and the expressed protein is purified from the host cell.

#### Brief Description of the Drawings

Figures 1A and 1B provide an amino acid sequence alignment of the 5'-nuclease domains of *Tma* DNA polymerase and DNA polymerases from seven species of the genus *Thermus*. Amino acids which are critical to the 5'-nuclease activity are indicated by asterisks.

Figures 2A, 2B, and 2C provide a sequencing trace from the cycle sequencing reaction using F730Y *Tma*30 DNA Polymerase as described in Example 5.

Figures 3A, 3B, and 3C provide a sequencing trace from the cycle sequencing reaction using AmpliTaq® DNA Polymerase FS as described in Example 5.

#### Detailed Description of the Invention

The present invention provides a mutant chimeric thermostable DNA polymerase and means for producing the enzyme. To facilitate understanding of the invention, a number of terms are defined below.

The terms "cell", "cell line", and "cell culture" can be used interchangeably and all such designations include progeny. Thus, the words "transformants" or "transformed cells" include the primary transformed cell and cultures derived from that cell without regard to the number of transfers. All progeny may not be precisely identical in DNA content, due to deliberate or inadvertent mutations. Mutant progeny that have the same functionality as screened for in the originally transformed cell are included in the definition of transformants.

The term "control sequences" refers to DNA sequences necessary for the expression of an operably linked coding sequence in a particular host organism. The control sequences that are suitable for procaryotes, for example, include a promoter, optionally an operator sequence, a ribosome binding site, positive retroregulatory elements (see U.S. Patent No. 4,666,848, incorporated herein by reference), and possibly other sequences. Eucaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.

The term "expression clone" refers to DNA sequences containing a desired coding sequence and control sequences in operable linkage, so that hosts transformed with these sequences are capable of producing the encoded proteins. The term "expression system" refers to a host transformed with an expression clone. To effect transformation, the expression clone may be included on a vector; however, the relevant DNA may also be integrated into the host chromosome.

The term "gene" refers to a DNA sequence that comprises control and coding sequences necessary for the production of a recoverable bioactive polypeptide or precursor.

The term "operably linked" refers to the positioning of the coding sequence such that control sequences will function to drive expression of the protein encoded by the coding sequence. Thus, a coding sequence "operably linked" to control sequences refers to a configuration wherein the coding sequences can be expressed under the direction of a control sequence.

The term "oligonucleotide" as used herein is defined as a molecule comprised of two or more deoxyribonucleotides or ribonucleotides. The exact size will depend on many factors, which in turn depends on the ultimate function or use of the oligonucleotide. Oligonucleotides can be prepared by any suitable method, including, for example, cloning and restriction of appropriate sequences and direct chemical synthesis by a method such as the phosphotriester method of Narang *et al.*, 1979, Meth. Enzymol. 68:90-99; the phosphodiester method of Brown *et al.*, 1979, Meth. Enzymol. 68:109-151; the diethylphosphoramidite method of Beaucage *et al.*, 1981, Tetrahedron Lett. 22:1859-1862; and the solid support method of U.S. Patent No. 4,458,066, each incorporated herein by reference. A review of synthesis methods is provided in Goodchild, 1990, Bioconjugate Chemistry 1(3): 165-187, incorporated herein by reference.

The term "primer" as used herein refers to an oligonucleotide which is capable of acting as a point of initiation of synthesis when placed under conditions in which primer extension is initiated. Synthesis of a primer extension product which is complementary to a nucleic acid strand is initiated in the presence of the requisite four different nucleoside triphosphates and a thermostable DNA polymerase in an appropriate buffer at a suitable temperature. A "buffer" includes cofactors (such as divalent metal ions) and salt (to provide the appropriate ionic strength), adjusted to the desired pH.

A primer that hybridizes to the non-coding strand of a gene sequence (equivalently, is a subsequence of the coding strand) is referred to herein as an "upstream" primer. A primer that hybridizes to the coding strand of a gene sequence is referred to herein as an "downstream" primer.

The terms "restriction endonucleases" and "restriction enzymes" refer to enzymes, typically bacterial in origin, which cut double-stranded DNA at or near a specific nucleotide sequence.

The term "thermostable enzyme", as used herein, refers to an enzyme which is stable to heat and has an elevated temperature reaction optimum. The thermostable enzyme of the present invention catalyzes primer extension optimally at a temperature between 60 and 90°C, and is usable under the temperature cycling conditions typically used in cycle sequence reactions and polymerase chain reaction amplifications (described in U.S. Patent No. 4,965,188, incorporated herein by reference).

As used herein, a "point mutation" in an amino acid sequence refers to either a single amino acid substitution or single amino acid deletion. A point mutation preferably is introduced into an amino acid sequence by a suitable codon change in the encoding DNA.

Individual amino acids in a sequence are represented herein as AN, wherein A is the standard one letter symbol for the amino acid in the sequence, and N is the position in the sequence. Mutations within an amino acid sequence are represented herein as A<sub>1</sub>NA<sub>2</sub>, wherein A<sub>1</sub> is the standard one letter symbol for the amino acid in the unmutated protein sequence, A<sub>2</sub> is the standard one letter symbol for the amino acid in the mutated protein sequence, and N is the position in the amino acid sequence. For example, a G46D mutation represents a change from glycine to aspartic acid at amino acid position 46. The amino acid positions are numbered based on the full-length sequence of the protein from which the region encompassing the mutation is derived. Thus, in the present invention, mutations in the region of the protein which are derived from a *Thermus* species DNA polymerase are numbered according to the full-length *Thermus* species DNA polymerase sequence, whereas mutations in the region derived from *Tma* DNA polymerase are numbered according to the full-length *Tma* DNA polymerase sequence. Representations of nucleotides and point mutations in DNA sequences are analogous.

As used herein, a "chimeric" protein refers to a protein whose amino acid sequence represents a fusion product of subsequences of the amino acid sequences from at least two distinct proteins. A chimeric protein preferably is not produced by direct manipulation of amino acid sequences, but, rather, is expressed from a "chimeric" gene that encodes the chimeric amino acid sequence. The chimeric proteins of the present invention consist of an amino-terminal (N-terminal) region derived from a *Thermus* species DNA polymerase and a carboxy-terminal (C-terminal) region derived from *Tma* DNA polymerase. The N-terminal region refers to a region extending from the N-terminus (amino acid position 1) to an internal amino acid. Similarly, the C-terminal region refers to a region extending from an internal amino acid to the C-terminus. In the chimeric proteins of the present invention, the N-terminal region extends from the N-terminus (amino acid position 1) to the beginning of the C-terminal region, which extends to the C-terminus. Thus, taken together, the N-terminal and C-terminal regions encompass the entire amino acid sequence.

The exonucleolytic activities associated with DNA polymerases (3' to 5' exonuclease activity and 5'-nuclease activity, also referred to as 5' to 3' exonuclease activity) and methods of measuring these activities are well known in the art. As used herein, an activity is "substantially reduced" if reduced to less than about 20%, preferably to less than about 10%, and more preferably to less than about 1%, of the activity present in the unmutated enzyme. An activity is "inactivated" or "essentially inactivated" if reduced to a level which is negligible for the purpose of the enzyme's typical or preferred use.

#### The thermostable DNA polymerase of the Invention

The typical thermostable DNA polymerase of the present invention is a chimeric DNA polymerase in which the N-terminal region consists of an N-terminal region of a *Thermus* species DNA polymerase and the C-terminal region con-

sists of a C-terminal region of *Tma* DNA polymerase. The N-terminal region from the *Thermus* species DNA polymerase encompasses a portion of, or all of, the 5'-nuclease domain. The C-terminal region from *Tma* DNA polymerase encompasses a portion, or possibly none, of the 5'-nuclease domain and the entire 3' to 5' exonuclease and DNA polymerase domains. The portion of the 5'-nuclease domain of *Tma* DNA polymerase encompassed by the C-terminal region of the chimeric protein will correspond to that portion of the 5'-nuclease domain of the *Thermus* species DNA polymerase not encompassed by the N-terminal region of the chimeric protein.

The chimeric DNA polymerase additionally contains the F730Y mutation, which increases the efficiency with which the DNA polymerase incorporates ddNTPs. The chimeric DNA polymerase preferably also contains one or more point mutations which significantly reduce or eliminate the 5'-nuclease activity and one or more point mutations which significantly reduce or eliminate the 3' to 5' exonuclease activity.

#### 1. The chimeric protein domains

DNA polymerases from species of the genus *Thermus* and *Tma* DNA polymerase are similar in overall structure. In these DNA polymerases, the exonuclease and DNA polymerase activities of the enzymes are present in discrete regions of the protein (the activity domains). The approximate activity domains of a representative *Thermus* species DNA polymerase, *Taq* DNA polymerase, and *Tma* DNA polymerase are shown in the table below (see also U.S. Patent No. 5,420,029). The homologous activity domains which encode 5'-nuclease activity, and those which encode DNA polymerase activity, are approximately the same length (see Figures 1A and 1B). The difference in length between the region that encodes 3' to 5' exonuclease activity in *Tma* DNA polymerase and the corresponding region in *Taq* DNA polymerase corresponds to the lack of 3' to 5' exonuclease activity in *Taq* DNA polymerase.

Activity Domains (approximate amino acid positions)			
	5'-nuclease	3'- to 5'exonuclease	Polymerase
<i>Taq</i> DNA polymerase	1-289	---	423-832
<i>Tma</i> DNA polymerase	1-291	292-484	485-893

Significant amino acid sequence similarity exists between *Thermus* species DNA polymerases and *Tma* DNA polymerase. For example, an amino acid sequence comparison of a representative *Thermus* species DNA polymerase, *Taq* DNA polymerase, and *Tma* DNA polymerase using the GAP computer program (Genetics Computer Group, Madison, WI) with the default parameter values, indicates that the amino acid sequences are approximately 44% identical and 66% similar over either the entire amino acid sequences or over the 5'-nuclease domains.

Because of the overall structural and sequence similarity, the chimeric enzyme preserves the overall structure and activity domains present in *Tma* DNA polymerase. The essential change is that the amino acid sequence of the N-terminal region of the chimeric enzyme is that of the corresponding region of a *Thermus* species DNA polymerase. Thus, the chimeric enzyme of the present invention corresponds to a mutated *Tma* DNA polymerase, wherein the 5'-nuclease domain has been replaced by the corresponding domain from a *Thermus* species DNA polymerase. The "corresponding domain" is defined herein by an amino acid sequence alignment, as provided in the figures.

Figures 1A and 1B provide an amino acid sequence alignment of the 5'-nuclease domains of *Tma* DNA polymerase and seven representative *Thermus* species DNA polymerases. The seven representative *Thermus* species DNA polymerases are listed in the table below, along with the abbreviations used herein and the sequence identification numbers for the amino acid sequences of the 5'-nuclease domains.

Abbreviation	Species	Sequence of the 5'-Nuclease Domain
<i>Tma</i>	<i>Thermatoga maritima</i>	(SEQ ID NO: 1)
<i>Taq</i>	<i>Thermus aquaticus</i>	(SEQ ID NO: 2)
<i>Tfl</i>	<i>Thermus flavus</i>	(SEQ ID NO: 3)
<i>Tth</i>	<i>Thermus thermophilus</i>	(SEQ ID NO: 4)

(continued)

Abbreviation	Species	Sequence of the 5'-Nuclease Domain
<i>TZ05</i>	<i>Thermus species Z05</i>	(SEQ ID NO: 5)
<i>Tca</i>	<i>Thermus caldofilus</i>	(SEQ ID NO: 6)
<i>Tsps17</i>	<i>Thermus species sps17</i>	(SEQ ID NO: 7)
<i>Tfi</i>	<i>Thermus filiformis</i>	(SEQ ID NO: 8)

The correspondence of amino acids and regions within these DNA polymerases is obtained from the amino acid sequence alignment. As used herein, amino acids "correspond" if they are aligned in the sequence alignment of Figures 1A and 1B. Thus, correspondence refers both to amino acids which are identical (conserved) among the sequences and to amino acids which are not identical, but which are aligned to maximize overall sequence homology.

A number of additional species of the genus *Thermus* have been identified and are available from depositories such as the American Type Culture Collection (ATCC) and the Deutsche Sammlung von Mikroorganismen (DSMZ). As discussed below, DNA polymerases and the encoding genes can be recovered from the deposited strains and sequenced in a routine manner. A routine sequence alignment of the amino acid sequence of a *Thermus* species DNA polymerase sequence with the *Tma* DNA polymerase sequence using, for example, the GAP program, will enable the use of the *Thermus* DNA polymerase sequence in a chimeric DNA polymerase of the present invention.

In the chimeric protein of the invention, the first amino acid of the region from *Tma* DNA polymerase will begin with the amino acid following the amino acid that corresponds to the last amino acid of the *Thermus* species DNA polymerase sequence and will contain the rest (through amino acid 893) of the *Tma* DNA polymerase sequence. The sequence of the entire *Tma* DNA polymerase is provided as SEQ ID NO: 10. Preferably, the amino acid sequence from the *Thermus* species DNA polymerase is joined to an amino acid sequence from *Tma* DNA polymerase at a point where the two amino acid sequences are identical or similar. For example, a preferred embodiment consists of amino acids 1-190 from *Taq* DNA polymerase and amino acids 191-893 of *Tma* DNA polymerase. Amino acid 190 of *Tma* DNA polymerase corresponds to amino acid 190 of *Taq* DNA polymerase, and the *Tma* DNA polymerase portion of the chimeric enzyme begins with the next amino acid, amino acid 191.

In regions where the two DNA polymerases are identical, identification of the last amino acid from the *Thermus* species DNA polymerase is arbitrary within the region. For example, because amino acids 191 and 192 are identical in *Taq* DNA polymerases and *Tma* DNA polymerases (and conserved among *Thermus* species DNA polymerase), a chimeric protein that contains amino acids 1-190 of *Taq* DNA polymerase is indistinguishable from chimeric proteins containing amino acids 1-191 or 1-192 of *Taq* DNA polymerase. The embodiment of the invention described in the examples is referred to as containing amino acids 1-190 of *Taq* DNA polymerase in view of the original derivation of the enzyme.

In the sequence alignment provided in Figures 1A and 1B, gaps one amino acid in length were inserted into the *Tma* DNA sequence at positions 54-55 and 225-226 to allow alignment with five of seven of the *Thermus* species DNA polymerases which contain an additional amino acid at these positions. Consequently, for these two amino acids present in these five *Thermus* species, there are no corresponding amino acids in *Tma* DNA polymerase. One of skill in the art will realize that a suitable chimeric protein containing a N-terminal region from one of these five *Thermus* species DNA polymerases that ends with an amino acid which is aligned with a gap in *Tma* DNA polymerase can be constructed in which the *Tma* DNA polymerase-derived region starts at the first amino acid following the gap.

A critical aspect of the chimeric DNA polymerase is that it is encoded by a chimeric gene in which the region encoding the *Tma* DNA polymerase sequence through at least the alternative ribosomal binding site present at about codons 133-137 in the full-length *Tma* DNA polymerase gene, and preferably through the methionine 140 start codon, is replaced by a gene sequence encoding the corresponding region from a *Thermus* species DNA polymerase. The presence in the full-length *Tma* DNA polymerase gene of this alternative ribosomal binding site and start codon results in the preferential expression of a truncated *Tma* DNA polymerase starting with amino acid 140. As described below, replacement of this region of the *Tma* DNA polymerase gene is critical to the efficient expression of the full-length chimeric protein. Thus, in the chimeric DNA polymerase of the invention, the N-terminal region from a *Thermus* species DNA polymerase replaces a region of *Tma* DNA polymerase that encompasses at least through amino acid 137, and preferably through amino acid 140.

The region of each *Thermus* species DNA polymerase that corresponds to amino acids 1-137 of *Tma* DNA polymerase is obtained from an amino acid sequence alignment, as provided in the figures. For example, the region of *Taq* DNA polymerase that corresponds to amino acids 1-137 of *Tma* DNA polymerase is amino acids 1-142 (see Figures 1A and 1B), and the amino acid of *Taq* DNA polymerase that corresponds M140 of *Tma* DNA polymerase is L145.

Thus, embodiments in which the N-terminal region is from *Taq* DNA polymerase will comprise at least amino acids 1-142 and preferably, amino acids 1-145 of *Taq* DNA polymerase. Similarly, for embodiments in which the N-terminal region is from another *Thermus* species DNA polymerase, the region of the *Thermus* species DNA polymerase that corresponds to amino acids 1-137 and 140 of *Tma* DNA polymerase is obtained from the sequence alignment provided in the figures.

One of skill in the art will recognize that minor mutations, additions, or deletions can be introduced into a DNA polymerase that do not alter the functional properties of the enzyme, and that such a mutated enzyme is equivalent, for all intents and purposes, to the unmutated enzyme. For example, it is known that a deletion in *Taq* DNA polymerase of several N-terminal amino acids does not alter the functional properties of the enzyme. Similarly, it is known that substitution mutations at many of the amino acid positions appear to have essentially no effect. For the purposes of the present invention, DNA polymerases which contain minor mutations that do not alter the functional properties of the enzyme are considered to be equivalent to the unmutated DNA polymerase.

## 2. Point mutations in the 5'-nuclease domain

In one embodiment, the 5'-nuclease domain of the chimeric DNA polymerase contains one or more point mutations (single amino acid substitution or deletion mutations) which reduce or eliminate the 5'-nuclease activity. Because the 5'-nuclease domain of the chimeric protein contains portions derived from a *Thermus* species DNA polymerase and, in most embodiments, from *Tma* DNA polymerase, mutations which substantially reduce or eliminate the 5'-nuclease activity may be introduced either into the *Thermus* species DNA polymerase-derived portion or the *Tma* DNA polymerase-derived portion.

Based on amino acid sequence alignments, DNA polymerases have been classified into groups, designated families A, B, and C, according to the homology with *E. coli* DNA polymerases I, II, and III (see, for example, Ito and Braithwaite, *Nucl. Acids Res.* 19(15):4045-4-47, incorporated herein by reference). The *Tma* and *Thermus* species DNA polymerases are members of the family A DNA polymerases, which are related to *E. coli* DNA polymerase I. Amino acids which are conserved among family A DNA polymerases and which are critical to 5'-nuclease activity of the DNA polymerases have been identified (see, for example, Gutman *et al.* 1993, *Nucl. Acids. Res.* 21:4406-4407, incorporated herein by reference). Because of the conservation of amino acids which are critical for 5'-nuclease activity in family A DNA polymerases, the identification of critical amino acids in one DNA polymerase, such as *E. coli* DNA polymerase I or *Taq* DNA polymerase, allows identification of critical amino acids in other family A DNA polymerases based on a sequence alignment, such as provided in Figures 1A and 1B. Critical amino acids can be identified in additional *Thermus* species DNA polymerases from a routine sequence alignment with the sequences provided herein.

Amino acids that have been identified as critical to 5'-nuclease activity are indicated in Figures 1A and 1B with an asterisk. The positions of the critical amino acids within each DNA polymerase is obtained from the alignment. For example, referring the *Taq* DNA polymerase sequence, (SEQ ID NO: 2), these critical amino acids are as follows: D18, R25, G46, D67, F73, R74, Y81, G107, E117, D119, D120, D142, D144, G187, D188, D191, and G195.

It would not be surprising if additional critical amino acids are identified in the future. As mutations at these amino acid positions as described herein would result in a reduction or eliminating of the 5'-nuclease activity, such mutations would be suitable for use in the present invention.

In general, to reduce or eliminate 5'-nuclease activity, one or more of these amino acid positions is either deleted or mutated to an amino acid having a different property. For example, an acidic amino acid such as Asp (D) may be changed to a basic (Lys, Arg, His), neutral (Ala, Val, Leu, Ile, Pro, Met, Phe, Trp), or polar but uncharged amino acid (Gly, Ser, Thr, Cys, Tyr, Asn, or Gln). The preferred G46D mutation substitutes the acidic Asp for the polar but uncharged Gly. In general, mutations to Ala or Gly are preferable to minimize distortion of the protein structure.

Substitution mutations which preserve the charge property of the amino acid also may attenuate the 5'-nuclease activity. For example, U.S. Patent 5,474,920, incorporated herein by reference, describes three mutations in the *Taq* DNA sequence which reduce or eliminate the 5'-nuclease activity. Although one of the mutations, R25C (basic to polar but uncharged), results in a change to an amino acid having a different property, two of the mutations: F73L (neutral to neutral) and R74H (basic to basic), do not result in a change in property. Nevertheless, all three mutations attenuate the 5'-nuclease activity. Particular mutations at each critical amino acid position which affect the 5'-nuclease activity can be determined routinely by mutating the DNA polymerase and measuring the resulting activity. A sensitive and convenient assay is described in U.S. Patent 5,466,591, incorporated herein by reference.

In a preferred embodiment, the 5'-nuclease domain of the chimeric DNA polymerase contains a mutation corresponding to a G46D mutation in *Taq* DNA polymerase, which reduces the 5'-nuclease activity at least 1000-fold (see U.S. Patent 5,466,591).

Mutations in the amino acid sequence are achieved by incorporating appropriate mutations in the encoding gene sequence. Such mutations in the DNA sequence are carried out using techniques well known in the art, as described further, below.



### 3. Point mutations in the 3' to 5' exonuclease domain

In one embodiment, the 3' to 5' exonuclease domain of the chimeric DNA polymerase contains one or more point mutations (single amino acid substitution or deletion mutations) which reduce or eliminate the 3' to 5' exonuclease activity. The 3' to 5' exonuclease domain of the chimeric protein is contained within the *Tma* DNA polymerase-derived portion. Thus, suitable mutations are those which substantially reduce or eliminate the 5'-nuclease activity of *Tma* DNA polymerase.

Three amino acid "motifs" critical for 3' to 5' exonuclease activity in *Tma* DNA polymerase, along with the critical amino acids within each motif, have been identified (see U.S. Patent No. 5,420,029). The critical amino acids are listed below. Mutations of one or more of these amino acids which reduce the 3' to 5' exonuclease activity in *Tma* DNA polymerase may be used in the DNA polymerases of the present invention.

<i>Tma</i> DNA polymerase Amino Acids Critical to 3' to 5' exonuclease Activity	
Motif	Critical Amino acids
A	D323, E325, L329
B	N385, D389, L393
C	Y464, D468

It would not be surprising if additional critical amino acids are identified in the future. As mutations at these amino acid positions as described herein would result in a reduction or eliminating of the 3' to 5' exonuclease activity, such mutations would be suitable for use in the present invention.

As described above for the reduction of 5'-nuclease activity, reduction or elimination of 3' to 5' exonuclease activity is achieved by a substitution or deletion mutation at one or more of these critical amino acid positions, preferably a substitution mutation to an amino acid having a different property. In the preferred embodiment, the 3' to 5' exonuclease domain of *Tma* DNA polymerase is mutated by D323A and E325A mutations, which together essentially eliminate the 3' to 5' exonuclease activity.

Mutations in the amino acid sequence are achieved by incorporating appropriate mutations in the encoding gene sequence. Such mutations in the DNA sequence are carried out using techniques well known in the art, as described further below.

#### Advantages of the DNA polymerase of the invention

The chimeric thermostable DNA polymerase of the invention represents a significant improvement over thermostable DNA polymerases described in the literature. In particular, the DNA polymerase of the invention provides the following combination of properties:

- improved uniformity of peak heights in DNA sequencing traces, in particular when used with dye-labeled ddNTPs in a cycle sequencing reaction;
  - reduced rate of pyrophosphorolysis of dye-labeled ddNTPs; and
  - improved incorporation of dITP.
- Furthermore, the DNA polymerase can be easily and efficiently expressed to a high level in a recombinant expression system, thereby facilitating commercial production of the enzyme.

The combination of properties possessed by the DNA polymerase of the invention is particularly useful in dye-terminator cycle sequencing reactions, and provides significantly improved results. Each of these properties is discussed below.

#### 1. Improved incorporation of ddNTPs

The chimeric DNA polymerase of the present invention contains the F730Y mutation, which is known to increase the efficiency of incorporation of ddNTPs.

By comparison, AmpliTaq® DNA polymerase FS is a mutated form of *Taq* DNA polymerase that contains the analogous mutation (F667Y). AmpliTaq® DNA polymerase FS also exhibits an increased efficiency of incorporation of ddNTPs, but lacks several the other properties exhibited by the DNA polymerase of the present invention.

## 2. Improved uniformity of peak heights in DNA sequencing traces


An advantageous property of the DNA polymerase of the present invention is that, when used in a dye-terminator cycle sequencing reaction, it results in uniform peak heights in the sequencing trace (also referred to as chromatograms or electropherograms). Uneven peak heights can decrease the accuracy of base calling and make mutation and polymorphism detection more difficult.

Unevenness of peak heights in dye-terminator cycle sequencing reactions is a problem that previously had not been solved. For example, although AmpliTaq® DNA Polymerase FS incorporates ddNTPs more efficiently than does unmutated *Taq* DNA polymerase, the peak height patterns obtained in dye-terminator sequencing reactions are uneven (see Parker *et al.*, 1996, *BioTechniques* 21(4):694-699, incorporated herein by reference). The unevenness results at least partially from a dependence of peak height on the sequence context. For example, the peak height obtained from a G following an A can be extremely small, making an accurate base call difficult. Conversely, the peak height obtained from an A following an G can be very high. Particularly problematical patterns include G after A or C, A after A or C, and T after T, which can result in very low peak heights. Very high peak heights, such as results from A after G, are less problematical alone, but can render adjacent low signals unreadable.

As shown in the examples, the use of the chimeric DNA polymerase of the invention in cycle sequencing reactions results in significantly more uniform peak heights than obtained using AmpliTaq® DNA Polymerase FS. The improved uniformity in peak height results in a significant increase in the accuracy of base calling and makes mutation and polymorphism detection easier.

## 3. Reduced rate of pyrophosphorolysis of dye-labeled ddNTPs

DNA polymerases catalyze the template-dependent incorporation of a deoxynucleotide onto the 3'-hydroxyl terminus of a primer, with the concomitant release of inorganic pyrophosphate (PPi). This polymerization reaction is reversible. DNA polymerases also catalyze the reverse reaction, pyrophosphorolysis, which is the degradation of DNA in the presence of PPi. The reaction is summarized below:



Inorganic pyrophosphatase (PPase), also known as pyrophosphate phosphohydrolase, catalyzes hydrolysis of inorganic pyrophosphate (PPi) to two molecules of orthophosphate. PPase plays a vital role in RNA and DNA synthesis in vivo. By cleaving PPi, the enzyme shifts the overall equilibrium in favor of synthesis.

Pyrophosphorolysis can be detrimental to DNA sequencing reactions. Accuracy in DNA sequencing reactions depends on precise band position, a decrease in size of only one nucleotide can result in gel artifacts such as reduced or missing bands. Pyrophosphorolysis results in the removal of bases from the 3'- end of the primer extension product. Furthermore, removal of the incorporated terminal ddNMP (dideoxynucleosidemonophosphate) from a ddNMP-terminated fragment allows subsequent extension, which leads to signal strength reduction at the affected position and a reduced or missing peak in the electropherogram.

Thus, it is desirable to minimize the pyrophosphorolysis reaction in sequencing reactions. The addition of PPase to the reaction shifts the overall equilibrium in favor of synthesis by cleaving PPi. The use of PPase to improve sequencing reactions is described in Tabor and Richardson, 1990, *J. Biol. Chem.* 265(14):8322-8328; and in PCT Patent Publication No. WO 90/12111; both incorporated herein by reference. The commercially available cycle sequencing kits from Perkin Elmer (Norwalk, CT), which contain AmpliTaq® DNA Polymerase FS, contain PPase to reduce pyrophosphorolysis.

Surprisingly, cycle sequencing reactions using the DNA polymerase of the present invention are much less affected by pyrophosphorolysis of the dye-labeled ddNTP terminators. As described in the examples, cycle sequencing reactions carried out with a range of PPase concentrations from 0 to 20 units yielded essentially identical results. Thus, the DNA polymerase of the present invention appears to greatly reduce or eliminate the need for PPase in cycle sequencing reactions.

## 4. Improved incorporation of dITP

In a typical cycle sequencing reaction, dITP is used instead of dGTP in order to relieve compressions in G/C-rich regions. Incorporation of dITP into DNA reduces the denaturation temperature and facilitates denaturation of secondary

structure. Because DNA polymerases discriminate against dITP, which is an unconventional nucleotide, the relative concentration of dITP must be substantially increased in a reaction to obtain adequate incorporation. For example, in the reaction conditions optimized for AmpliTaq® DNA Polymerase FS, dITP is present at a concentration five-fold greater than the concentrations of dATP, dCTP, and dTTP.

In contrast, the DNA polymerase of the present invention incorporates dITP more efficiently, which allows the reaction to be carried out with more uniform dNTP concentrations. As described in the examples, a dITP concentration of only about two- to three-fold greater than the concentrations of dATP, dCTP, and dTTP is optimal for the DNA polymerase of the present invention.

## 5. Efficiency of expression

As described above, the chimeric enzyme of the present invention corresponds to a mutated *Tma* DNA polymerase, wherein the 5'-nuclease domain has been replaced by the corresponding domain from a *Thermus* species DNA polymerase. The enzyme is expressed from a chimeric gene which corresponds to a mutated *Tma* DNA polymerase gene, wherein the region of the gene that encodes the 5'-nuclease domain has been replaced by the corresponding region of the *Thermus* species DNA polymerase gene. A significant advantage of the chimeric gene is that it enables the expression of a full-length DNA polymerase in a recombinant expression system much more efficiently than is possible from the *Tma* DNA polymerase gene.

The expression of a full-length DNA polymerase from a recombinant expression system containing the full-length natural *Tma* DNA polymerase gene sequence is problematical because of the preferential expression of a truncated form of the protein (see U.S. Patent No. 5,420,029). The truncated protein, referred to as Met140 *Tma*, consists of amino acids 140-893 of the full-length protein and appears to result from translation beginning at the methionine at position 140. The presence of a putative ribosomal binding site at codons 133-137 further suggests that the truncated protein results from translation beginning at the internal methionine. The preferential expression of the Met140 *Tma* truncated protein represents a significant difficulty in expressing and purifying a full-length *Tma* DNA polymerase.

The chimeric DNA polymerase gene contains a *Thermus* species DNA polymerase gene sequence in a region corresponding at least through the alternative ribosomal binding site present at about codons 133-137 in the full-length *Tma* DNA polymerase gene, and preferably through the internal start codon, codon 140. Thus, the *Tma* DNA polymerase gene sequence up through the region containing the ribosomal binding site and, preferably, the start codon responsible for the translation of Met140 *Tma*, is replaced by the corresponding region of a *Thermus* species DNA polymerase gene. The corresponding region of a *Thermus* species DNA polymerase gene does not provide for the undesirable internal initiation of a truncated protein. As a result, a recombinant expression system containing the chimeric DNA polymerase gene expresses a full-length chimeric DNA polymerase exclusively.

## Preparation of the DNA polymerase of the invention

The DNA polymerase of invention is a chimeric enzyme that consists of a portion derived from a *Thermus* species DNA polymerase and a portion derived from *Tma* DNA polymerase. The chimeric enzyme is prepared from a chimeric gene, i.e., a DNA that encodes the chimeric enzyme and consists of a portion derived from the *Thermus* species DNA polymerase gene and a portion derived from the *Tma* DNA polymerase gene. The chimeric gene is produced from the *Thermus* species DNA polymerase gene and the *Tma* DNA polymerase gene using standard gene manipulation techniques well known in the field of molecular biology, as described in detail below.

The gene encoding *Tma* DNA polymerase is described in U.S. Patent Nos. 5,420,029 and 5,466,591. The nucleotide sequence of the *Tma* DNA polymerase gene, as well as the full amino acid sequence of the encoded protein, are described therein. Example 5 of the '029 patent describes the construction of a variety of plasmids containing the full-length *Tma* DNA polymerase gene starting with plasmids pTma01 (deposited as *Escherichia coli* DG101, pBSM:TmaXma7-1 under ATCC No. 68471 on November 7, 1990; redeposited as ATCC No. 98764 on May 22, 1998) and pTma04 (deposited as *Escherichia coli* DG101, pBSM:TmaXma11-1delta Ba/Bg1 under ATCC No. 68472 on November 7, 1990; redeposited as ATCC No. 98765 on May 22, 1998), such as plasmids pTma12-1 and pTma13. Any of these expression vectors is suitable as a source of the *Tma* DNA polymerase gene.

Genes encoding DNA polymerases from a number of *Thermus* species, including the nucleotide sequence of the DNA polymerase gene and the amino acid sequence of the encoded protein, have been described. A number of these genes are obtainable from publicly available plasmids. The genes from additional *Thermus* species are obtainable from the host organisms using methods described in U.S. Patent Nos. 5,079,352; 5,618,711; 5,455,170; 5,405,774; and 5,466,591; each incorporated by reference.

The gene encoding *Taq* DNA polymerase is described in U.S. Patent Nos. 5,079,352 and 5,466,591. The nucleotide sequence of the *Taq* DNA polymerase gene, as well as the full amino acid sequence of the encoded protein, are described therein. Examples V-VII of the '352 patent describes the construction of a variety of expression plasmids con-

taining the full-length *Taq* DNA polymerase gene starting with plasmids pFC83 (ATCC 67422 deposited on May 29, 1987; redeposited as ATCC No. 98763 on May 22, 1998) and pFC85 (ATCC 67421 deposited on May 29, 1987; redeposited as ATCC No. 98762 on May 22, 1998), such as plasmids pLSP1, pLSG2, pSYC1578, pLSG5, and pLSG6. Any of these expression vectors is suitable as a source of the *Taq* DNA polymerase gene.

The gene encoding *Tth* DNA polymerase, methods for obtaining the gene, and expression plasmids containing the gene are described in U.S. Patent No. 5,618,711 and 5,466,591.

The gene encoding *TZ05* DNA polymerase, methods for obtaining the gene, and expression plasmids containing the gene are described in U.S. Patent No. 5,455,170 and 5,466,591.

The gene encoding *Tsps17* DNA polymerase, methods for obtaining the gene, and expression plasmids containing the gene are described in U.S. Patent No. 5,405,774 and 5,466,591.

The *Tfi* DNA polymerase gene is described in Akhmetzjanov and Vakhitov, 1992, Nucleic Acids Research 20(21):5839, incorporated herein by reference.

The *Tfi* DNA polymerase gene can be recovered from ATCC 43280 using the methods described in the referenced patents (see also 1984, FEMS Microbiol. Lett. 22:149-153 (1984)).

The *Tca* DNA polymerase gene is described in Kwon, 1997, Mol. Cells 7(2): 264-271; and the nucleotide sequence is available under EMBL/GenBank Accession No. U62584.

Additional *Thermus* species DNA polymerase genes can be recovered using techniques described in the above cited patents from the following ATCC deposits: ATCC 43814 and 43815 (see Alfredsson, 1986, Appl. Environ. Microbiol. 52:1313-1316); ATCC 27978 (see Ramaley 1970 J. Bacteriol. 114:556-562; 1973; *ibid.* 103:527-528); ATCC 31674 (see U.S. Patent Nos. 4,442,214 and 4,480,036); ATCC 35948 (*T. ruber*, see Loginova 1984, Int. J. Syst. Bacteriol. 34:498-499). All references are incorporated herein by reference.

Additional *Thermus* species can be recovered using techniques described in the above cited patents from the following Deutsche Sammlung von Mikroorganismen (DSM) deposits: DSM:1279 (NUM: 2244) (see Loginova, *et al.*, 1975, Izv. Akad. Nauk SSSR Ser. Biol.: 304-307); DSM:579; DSM:625 (NUM: 2248) (see Degryse *et al.*, 1978, Arch. Microbiol. 189:196); DSM: 1279 (NUM: 3844) (see Loginova *et al.*, 1984, Int. J. Syst. Bacteriol.:498-499); and DSM:625(NUM: 1002) (see Brock and Freeze, 1969, J. Bacteriol.: 289-297). All references are incorporated herein by reference.

Additional *Thermus* species which have been described include *T. oshimai* (see Williams *et al.*, 1996, Int. J. Syst. Bacteriol. 46(2):403-408); *T. silvanus* and *T. chliarophilus* (see Tenreiro *et al.* 1995, Int. J. Syst. Bacteriol. 45(4):633-639); *T. scotoductus* (see Tenreiro *et al.*, 1995, Res. Microbiol. 146(4):315-324); and *T. ruber* (see Shadrina *et al.*, 1982, Mikrobiologiya 51(4):611-615); all incorporated herein by reference.

Following the guidance provided herein, and using only well known techniques, one skilled in the art will be able to prepare from the DNA polymerase genes any number of expression vectors containing a chimeric gene suitable for expressing the chimeric DNA polymerases of the invention in any of a variety of host systems.

In a preferred embodiment, the chimeric enzyme of the invention consists of amino acids 1-190 from *Taq* DNA polymerase and amino acids 191-893 from *Tma* DNA polymerase, both regions suitably mutated to eliminate associated exonuclease activity. This preferred embodiment can be constructed directly from the *Taq* DNA polymerase and *Tma* DNA polymerase genes, either obtained from the deposited plasmids described above or recovered from the host organisms. However, such chimeric DNA polymerases can be most easily constructed from plasmid pUC18:Tma25, which was deposited with the ATCC under accession No. 98443 on May 28, 1997.

Plasmid pUC18:Tma25 contains a chimeric gene that encodes a chimeric protein consisting of amino acids 1-190 from *Taq* DNA polymerase and amino acids 191-893 of *Tma* DNA polymerase. The chimeric protein encoded by pUC18:Tma25 contains the G46D mutation in the *Taq* DNA polymerase portion. The nucleotide sequence of the chimeric gene of pUC18:Tma25 is provided as SEQ ID NO: 9.

Suitable expression systems are constructed from pUC18:Tma25 by sub-cloning the chimeric gene into a suitable expression vector, introducing one or more point mutations which attenuate or eliminate the 3' to 5' exonuclease activity of the encoded protein, and introducing the F730Y mutation in the *Tma* DNA polymerase portion. The construction of a preferred expression system, which encodes a chimeric protein containing a G46D mutation in 5'-nuclease domain, D323A and E325A mutations in the 3' to 5' exonuclease domain, and a F730Y mutation in the *Tma* DNA polymerase portion, is described in the examples.

The nucleotide sequence of pUC18:Tma25 that encodes amino acids 1-190 of *Taq* DNA polymerase was derived from plasmid pRDA3-2, described in U.S. Patent No. 5,466,591, and, thus, encodes an amino acid sequence containing the G46D mutation described therein. The nucleotide sequence of pRDA3-2 and, hence, pUC18:Tma25, also contains additional mutations relative to the native *Taq* DNA polymerase gene sequence (SEQ ID NO: 9) which are silent, i.e., do not alter the amino acid sequence encoded.

Because of the redundancy in the genetic code, typically a large number of DNA sequences encode any given amino acid sequence and are, in this sense, equivalent. As described below, it may be desirable to select one or another equivalent DNA sequences for use in a expression vector, based on the preferred codon usage of the host cell

into which the expression vector will be inserted. The present invention is intended to encompass all DNA sequences which encode the chimeric enzyme. Thus, chimeric genes of the present invention are not limited to containing only sequences from the wild-type *Thermus* species and *Tma* DNA polymerase genes, but can contain any of the DNA sequences which encode a chimeric DNA polymerase of the present invention.

5 Production of the enzyme of the invention is carried out using a recombinant expression clone. The construction of the recombinant expression clone, the transformation of a host cell with the expression clone, and the culture of the transformed host cell under conditions which promote expression, can be carried out in a variety of ways using techniques of molecular biology well understood in the art. Methods for each of these steps are described in general below. Preferred methods are described in detail in the examples.

10 An operable expression clone is constructed by placing the coding sequence in operable linkage with a suitable control sequences in an expression vector. The vector can be designed to replicate autonomously in the host cell or to integrate into the chromosomal DNA of the host cell. The resulting clone is used to transform a suitable host, and the transformed host is cultured under conditions suitable for expression of the coding sequence. The expressed protein is isolated from the medium or from the cells, although recovery and purification of the protein may not be necessary in some instances.

15 Construction of suitable clones containing the coding sequence and a suitable control sequence employs standard ligation and restriction techniques that are well understood in the art. In general, isolated plasmids, DNA sequences, or synthesized oligonucleotides are cleaved, modified, and religated in the form desired. Suitable restriction sites can, if not normally available, be added to the ends of the coding sequence so as to facilitate construction of an expression clone.

20 Site-specific DNA cleavage is performed by treating with a suitable restriction enzyme (or enzymes) under conditions that are generally understood in the art and specified by the manufacturers of commercially available restriction enzymes. See, e.g., product catalogs from Amersham (Arlington Heights, IL), Boehringer Mannheim (Indianapolis, IN), and New England Biolabs (Beverly, MA). In general, about 1 µg of plasmid or other DNA is cleaved by one unit of enzyme in about 20 µl of buffer solution; in the examples below, an excess of restriction enzyme is generally used to ensure complete digestion of the DNA. Incubation times of about one to two hours at a temperature which is optimal for the particular enzyme are typical. After each incubation, protein is removed by extraction with phenol and chloroform; this extraction can be followed by ether extraction and recovery of the DNA from aqueous fractions by precipitation with ethanol. If desired, size separation of the cleaved fragments may be performed by polyacrylamide gel or agarose gel electrophoresis using standard techniques. See, e.g., Maxam *et al.*, Methods in Enzymology, 1980, 65:499-560.

30 Restriction-cleaved fragments with single-strand "overhanging" termini can be made blunt-ended (double-strand ends) by treating with the large fragment of *E. coli* DNA polymerase I (Klenow) in the presence of the four deoxynucleoside triphosphates (dNTPs) using incubation times of about 15 to 25 minutes at 20°C to 25°C in 50 mM Tris, pH 7.6, 50 mM NaCl, 10 mM MgCl<sub>2</sub>, 10 mM DTT, and 5 to 10 µM dNTPs. The Klenow fragment fills in at 5' protruding ends, but chews back protruding 3' single strands, even though the four dNTPs are present. If desired, selective repair can be performed by supplying one or more selected dNTPs, within the limitations dictated by the nature of the protruding ends. After treatment with Klenow, the mixture is extracted with phenol/chloroform and ethanol precipitated. Similar results can be achieved using S1 nuclease, because treatment under appropriate conditions with S1 nuclease results in hydrolysis of any single-stranded portion of a nucleic acid.

40 Ligations are performed in 15-30 µl volumes under the following standard conditions and temperatures: 20 mM Tris-Cl, pH 7.5, 10 mM MgCl<sub>2</sub>, 10 mM DTT, 33 µg/ml BSA, 10-50 mM NaCl, and either 40 µM ATP and 0.01-0.02 (Weiss) units T4 DNA ligase at 0°C (for ligation of fragments with complementary single-stranded ends) or 1 mM ATP and 0.3-0.6 units T4 DNA ligase at 14°C (for "blunt end" ligation). Intermolecular ligations of fragments with complementary ends are usually performed at 33-100 µg/ml total DNA concentrations (5-100 nM total ends concentration). Intermolecular blunt end ligations (usually employing a 20-30 fold molar excess of linkers, optionally) are performed at 1 µM total ends concentration.

45 In vector construction, the vector fragment is commonly treated with bacterial or calf intestinal alkaline phosphatase (BAP or CIAP) to remove the 5' phosphate and prevent religation and reconstruction of the vector. BAP and CIAP digestion conditions are well known in the art, and published protocols usually accompany the commercially available BAP and CIAP enzymes. To recover the nucleic acid fragments, the preparation is extracted with phenol-chloroform and ethanol precipitated to remove the phosphatase and purify the DNA. Alternatively, religation of unwanted vector fragments can be prevented by restriction enzyme digestion before or after ligation, if appropriate restriction sites are available.

50 In the construction set forth below, correct ligations for plasmid construction are confirmed by first transforming a suitable host, such as *E. coli* strain DG101 (ATCC 47043) or *E. coli* strain DG116 (ATCC 53606), with the ligation mixture. Successful transformants are selected by ampicillin, tetracycline or other antibiotic resistance or sensitivity or by using other markers, depending on the mode of plasmid construction, as is understood in the art. Plasmids from the transformants are then prepared according to the method of Clewell *et al.*, 1969, Proc. Nat. Acad. Sci. USA 62:1159, optionally following chloramphenicol amplification (Clewell, 1972, J. Bacteriol. 110:667). Alternatively, plasmid DNA can

be prepared using the "Base-Acid" extraction method at page 11 of the Bethesda Research Laboratories publication Focus 5(2), and very pure plasmid DNA can be obtained by replacing steps 12 through 17 of the protocol with CsCl/ethidium bromide ultracentrifugation of the DNA. The isolated DNA is analyzed by restriction enzyme digestion and/or sequenced by the dideoxy method of Sanger *et al.*, 1977, Proc. Natl. Acad. Sci. USA 74:5463 as further described by Messing *et al.*, 1981, Nuc. Acids Res. 9:309, or by the method of Maxam *et al.*, 1980, Methods in Enzymology 65:499.

The control sequences, expression vectors, and transformation methods are dependent on the type of host cell used to express the gene. Generally, procaryotic, yeast, insect, or mammalian cells are used as hosts. Procaryotic hosts are in general the most efficient and convenient for the production of recombinant proteins and are therefore preferred for the expression of the protein.

The procaryote most frequently used to express recombinant proteins is *E. coli*. However, microbial strains other than *E. coli* can also be used, such as bacilli, for example *Bacillus subtilis*, various species of *Pseudomonas*, and other bacterial strains, for recombinant expression of the protein. In such procaryotic systems, plasmid vectors that contain replication sites and control sequences derived from the host or a species compatible with the host are typically used.

For expression of constructions under control of most bacterial promoters, *E. coli* K12 strain MM294, obtained from the *E. coli* Genetic Stock Center under GCSC #6135, can be used as the host. For expression vectors with the P<sub>L</sub>N<sub>RBS</sub> or P<sub>L</sub>T<sub>7</sub>R<sub>BS</sub> control sequence, *E. coli* K12 strain MC1000 lambda lysogen, N<sub>7</sub>N<sub>53</sub>Cl857 SusP<sub>80</sub>, ATCC 39531, may be used. *E. coli* DG116, which was deposited with the ATCC (ATCC 53606) on April 7, 1987, and *E. coli* KB2, which was deposited with the ATCC (ATCC 53075) on March 29, 1985, are also useful host cells. For M13 phage recombinants, *E. coli* strains susceptible to phage infection, such as *E. coli* K12 strain DG98 (ATCC 39768), are employed. The DG98 strain was deposited with the ATCC on July 13, 1984.

For example, *E. coli* is typically transformed using derivatives of pBR322, described by Bolivar *et al.*, 1977, Gene 2:95. Plasmid pBR322 contains genes for ampicillin and tetracycline resistance. These drug resistance markers can be either retained or destroyed in constructing the desired vector and so help to detect the presence of a desired recombinant. Commonly used procaryotic control sequences, i.e., a promoter for transcription initiation, optionally with an operator, along with a ribosome binding site sequence, include the  $\beta$ -lactamase (penicillinase) and lactose (lac) promoter systems (Chang *et al.*, 1977, Nature 198:1056), the tryptophan (trp) promoter system (Goeddel *et al.*, 1980, Nuc. Acids Res. 8:4057), and the lambda-derived P<sub>L</sub> promoter (Shimatake *et al.*, 1981, Nature 292:128) and gene N ribosome binding site (N<sub>RBS</sub>). A portable control system cassette is set forth in U.S. Patent No. 4,711,845, issued December 8, 1987. This cassette comprises a P<sub>L</sub> promoter operably linked to the N<sub>RBS</sub> in turn positioned upstream of a third DNA sequence having at least one restriction site that permits cleavage within six base pairs 3' of the N<sub>RBS</sub> sequence. Also useful is the phosphatase A (phoA) system described by Chang *et al.*, in European Patent Publication No. 196,864, published October 8, 1986. However, any available promoter system compatible with procaryotes can be used to construct an expression vector of the invention.

In addition to bacteria, eucaryotic microbes, such as yeast, can also be used as recombinant host cells. Laboratory strains of *Saccharomyces cerevisiae*, Baker's yeast, are most often used, although a number of other strains are commonly available. While vectors employing the two micron origin of replication are common (Broach, 1983, Meth. Enz. 101:307), other plasmid vectors suitable for yeast expression are known (see, for example, Stinchcomb *et al.*, 1979, Nature 282:39; Tschempe *et al.*, 1980, Gene 10:157; and Clarke *et al.*, 1983, Meth. Enz. 101:300). Control sequences for yeast vectors include promoters for the synthesis of glycolytic enzymes (Hess *et al.*, 1968 J. Adv. Enzyme Reg. 7:149; Holland *et al.*, 1978, Biotechnology 17:4900; and Holland *et al.*, 1981, J. Biol. Chem. 256:1385). Additional promoters known in the art include the promoter for 3-phosphoglycerate kinase (Hitzeman *et al.*, 1980 J. Biol. Chem. 255:2073) and those for other glycolytic enzymes, such as glyceraldehyde 3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase. Other promoters that have the additional advantage of transcription controlled by growth conditions are the promoter regions for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, and enzymes responsible for maltose and galactose utilization (Holland, *supra*).

Terminator sequences may also be used to enhance expression when placed at the 3' end of the coding sequence. Such terminators are found in the 3' untranslated region following the coding sequences in yeast-derived genes. Any vector containing a yeast-compatible promoter, origin of replication, and other control sequences is suitable for use in constructing yeast expression vectors.

The coding sequence can also be expressed in eucaryotic host cell cultures derived from multicellular organisms. See, for example, Tissue Culture, Academic Press, Cruz and Patterson, editors (1973). Useful host cell lines include COS-7, COS-A2, CV-1, murine cells such as murine myelomas N51 and VERO, HeLa cells, and Chinese hamster ovary (CHO) cells. Expression vectors for such cells ordinarily include promoters and control sequences compatible with mammalian cells such as, for example, the commonly used early and late promoters from Simian Virus 40 (SV 40) (Fiers *et al.*, 1978, Nature 273:113), or other viral promoters such as those derived from polyoma, adenovirus 2, bovine

papilloma virus (BPV), or avian sarcoma viruses, or immunoglobulin promoters and heat shock promoters. A system for expressing DNA in mammalian systems using a BPV vector system is disclosed in United States Patent No. 4,419,446. A modification of this system is described in U.S. Patent No. 4,601,978. General aspects of mammalian cell host system transformations have been described by Axel, U.S. Patent No. 4,399,216. "Enhancer" regions are also important in optimizing expression; these are, generally, sequences found upstream of the promoter region. Origins of replication may be obtained, if needed, from viral sources. However, integration into the chromosome is a common mechanism for DNA replication in eucaryotes.

Plant cells can also be used as hosts, and control sequences compatible with plant cells, such as the nopaline synthase promoter and polyadenylation signal sequences (Depicker *et al.*, 1982, *J. Mol. Appl. Gen.* 1:561) are available. Expression systems employing insect cells utilizing the control systems provided by baculovirus vectors have also been described (Miller *et al.*, in *Genetic Engineering* (1986), Setlow *et al.*, eds., Plenum Publishing, Vol. 8, pp. 277-297). Insect cell-based expression can be accomplished in *Spodoptera frugiperda*. These systems are also successful in producing recombinant enzymes.

Depending on the host cell used, transformation is done using standard techniques appropriate to such cells. The calcium treatment employing calcium chloride, as described by Cohen, 1972, *Proc. Natl. Acad. Sci. USA* 69:2110 is used for procaryotes or other cells that contain substantial cell wall barriers. Infection with *Agrobacterium tumefaciens* (Shaw *et al.*, 1983, *Gene* 23:315) is used for certain plant cells. For mammalian cells, the calcium phosphate precipitation method of Graham and van der Eb, 1978, *Virology* 52:546 is preferred. Transformations into yeast are carried out according to the method of Van Solingen *et al.*, 1977, *J. Bact.* 130:946, and Hsiao *et al.*, 1979, *Proc. Natl. Acad. Sci. USA* 76:3829.

It may be desirable to modify the sequence of the DNA encoding the enzyme of the invention to provide, for example, a sequence more compatible with the codon usage of the host cell without modifying the amino acid sequence of the encoded protein. Such modifications to the initial 5-6 codons may improve expression efficiency. DNA sequences which have been modified to improve expression efficiency, but which encode the same amino acid sequence, are considered to be equivalent and encompassed by the present invention.

A variety of site-specific primer-directed mutagenesis methods are available and well-known in the art (see, for example, Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor, 1989, second edition, chapter 15.51, "Oligonucleotide-mediated mutagenesis," which is incorporated herein by reference). The polymerase chain reaction (PCR) can be used to perform site-specific mutagenesis. In another technique now standard in the art, a synthetic oligonucleotide encoding the desired mutation is used as a primer to direct synthesis of a complementary nucleic acid sequence contained in a single-stranded vector, such as pBSM13+ derivatives, that serves as a template for construction of the extension product of the mutagenizing primer. The mutagenized DNA is transformed into a host bacterium, and cultures of the transformed bacteria are plated and identified. The identification of modified vectors may involve transfer of the DNA of selected transformants to a nitrocellulose filter or other membrane and the "lifts" hybridized with kinased synthetic mutagenic primer at a temperature that permits hybridization of an exact match to the modified sequence but prevents hybridization with the original unmutagenized strand. Transformants that contain DNA that hybridizes with the probe are then cultured (the sequence of the DNA is generally confirmed by sequence analysis) and serve as a reservoir of the modified DNA.

Once the protein has been expressed in a recombinant host cell, purification of the protein may be desired. A variety of purification procedures can be used to purify the recombinant thermostable DNA polymerase of the invention. Examples include the methods for purifying *Taq* DNA polymerase described in U.S. Patent No. 4,889,818; 5,352,600; and 5,079,352; the methods for purifying the DNA polymerase from *Thermus thermophilus* (*Tth*) described in U.S. Patent Nos. 5,618,711 and 5,310,652; the methods for purifying *Tma* DNA polymerase described in U.S. Patent Nos. 5,374,553 and 5,420,029. Methods for purifying these DNA polymerases are also described in U.S. Patent No. 5,466,591. All of the above patents are incorporated herein by reference.

In a preferred method, the expression of the DNA polymerase is carried out in *E. coli*, which is a mesophilic bacterial host cell. Because *E. coli* host proteins are heat-sensitive, the recombinant thermostable DNA polymerase can be substantially enriched by heat inactivating the crude lysate. This step is done in the presence of a sufficient amount of salt (typically 0.2-0.4 M ammonium sulfate) to reduce ionic interactions of the DNA polymerase with other cell lysate proteins.

Activity of the purified DNA polymerase is assayed as described in Lawyer *et al.*, 1989, *J. Biol. Chem.* 264:6427, incorporated herein by reference.

For long-term stability, the purified DNA polymerase enzyme must be stored in a buffer that contains one or more non-ionic polymeric detergents. Such detergents are generally those that have a molecular weight in the range of approximately 100 to 250,00 preferably about 4,000 to 200,000 daltons and stabilize the enzyme at a pH of from about 3.5 to about 9.5, preferably from about 4 to 8.5. Examples of such detergents include those specified on pages 295-298 of McCutcheon's *Emulsifiers & Detergents*, North American edition (1983), published by the McCutcheon Division of MC Publishing Co., 175 Rock Road, Glen Rock, NJ (USA), the entire disclosure of which is incorporated herein by ref-



erence. Preferably, the detergents are selected from the group comprising ethoxylated fatty alcohol ethers and lauryl ethers, ethoxylated alkyl phenols, octylphenoxy polyethoxy ethanol compounds, modified oxyethylated and/or oxypropylated straight-chain alcohols, polyethylene glycol monooleate compounds, polysorbate compounds, and phenolic fatty alcohol ethers. More particularly preferred are Tween 20<sup>TM</sup>, a polyoxyethylated (20) sorbitan monolaurate from ICI Americas Inc. (Wilmington, DE), and Iconol<sup>TM</sup> NP-40, an ethoxylated alkyl phenol (nonyl) from BASF Wyandotte Corp. (Parsippany, NJ).

The thermostable enzyme of this invention may be used for any purpose in which a thermostable DNA polymerase is necessary or desired. In a preferred embodiment, the enzyme is for DNA sequencing (see Innis *et al.*, 1988, Proc. Natl. Acad. Sci. USA 85:9436-9440, incorporated herein by reference).

The following examples are offered by way of illustration only and are by no means intended to limit the scope of the claimed invention. In these examples, all percentages are by weight if for solids and by volume if for liquids, unless otherwise noted.

### Example 1

#### Construction of an Expression System

An expression system is constructed from the deposited plasmid, pUC18:Tma25, which contains the gene having nucleotide sequence SEQ ID NO: 9, using conventional techniques well known in the art. The steps involved, which are described in more detail below, are as follows.

- The DNA polymerase coding sequence contained in pUC18:Tma25 is subcloned into a pDG160 expression vector, resulting in plasmid pTMA25.
- The D323A and E325A mutations are added to pTMA25 by site-specific primer-directed mutagenesis, resulting in plasmid pTMA30.
- The mutated gene coding sequence from pTMA30 is then subcloned into a pDG184 expression vector such that codons 1-283 are deleted, resulting in plasmid pTMA31.
- The F730Y mutation is added to pTMA31 by site-specific primer-directed mutagenesis, resulting in plasmid pTMA31[F730Y].
- A fragment of the mutated coding sequence from pTMA31[F730Y] containing the F730Y mutation is subcloned into pTMA30 to replace the corresponding unmutated fragment, resulting in plasmid pTMA30[F730Y].

Following each mutagenesis or sub-cloning step, *E. coli* strain DG116 host cells are transformed with the plasmid constructs. Ampicillin resistant (plasmid containing) colonies are screened for the presence of the desired plasmid using standard methods. Typically, first colonies are selected for the presence of a plasmid of the expected size by gel electrophoretic size fractionation. Candidate colonies are further screened for plasmids exhibiting the expected fragment pattern following digestion with one or more restriction enzymes. Finally, mutagenized sites and ligation junctions are sequenced to confirm the intended sequence.

Plasmid pDG160 is described in U.S. Patent No. 5,618,711, incorporated herein by reference. Plasmid pDG160 is a cloning and expression vector that comprises the bacteriophage  $\lambda$  P<sub>L</sub> promoter and gene N ribosome binding site (see U.S. Patent No. 4,711,845, incorporated herein by reference), a restriction site polylinker positioned so that sequences cloned into the polylinker can be expressed under the control of the  $\lambda$  P<sub>L</sub> promoter and gene N ribosome binding site, and a transcription terminator from the *Bacillus thuringiensis* delta-toxin gene (see U.S. Patent No. 4,666,848, incorporated herein by reference). Plasmid pDG160 also carries a mutated *RNAII* gene, which renders the plasmid temperature sensitive for copy number (see U.S. Patent No. 4,631,257, incorporated herein by reference).

These elements act in concert to make plasmid pDG160 a very useful and powerful expression vector. At 30-32°C, the copy number of the plasmid is low, and in a host cell that carries a temperature-sensitive repressor gene, such as *cl857*, the P<sub>L</sub> promoter does not function. At 37-41°C, however, the copy number of the plasmid is 50-fold higher than at 30-32°C, and the *cl857* repressor is inactivated, allowing the P<sub>L</sub> promoter to function. Plasmid pDG160 also carries an ampicillin resistance (Amp<sup>R</sup>) marker. In summary, plasmid pDG160 comprises the Amp<sup>R</sup> marker, the P<sub>L</sub> promoter and gene N ribosome binding site, a polylinker, and the BT *cry* PRE (BT positive retroregulatory element, U.S. Patent No. 4,666,848) in a ColE1 *cop<sup>ts</sup>* vector.

Plasmid pDG184 is described in U.S. Patent No. 5,420,029, incorporated herein by reference. Plasmid pDG184 is a derivative of pDG160, modified to include an *Nco* I site at the start codon of the inserted gene. The rest of the plasmid is functionally unchanged from pDG160.



I. Sub-cloning I

The DNA polymerase coding sequence is subcloned from plasmid pUC18:Tma25 into a pDG160 expression plasmid as follows:

5

A. Plasmid pUC18:Tma25, a 5347 base pair (bp) plasmid, is linearized by digestion with *Nsp* V, which cuts once at position 2084 (numbered starting with the first nucleotide of the coding sequence).

10

B. The linearized plasmid resulting from the *Nsp* V digestion is digested further with *Bam* HI, which cuts at nucleotide (nt) positions 1661, 1989, 2039, and 2686. A 602 bp *Nsp* V/*Bam* HI fragment (nt 2085-2686) containing the 3' end of the DNA polymerase gene is gel purified.

C. In a separate reaction, linearized plasmid resulting from the *Nsp* V digestion is digested further with *Hind* III, which cuts at positions 2629 and 5342. A 2089 bp *Nsp* V/*Hind* III fragment (nt 5343-2084) containing the 5' end of the DNA polymerase gene is gel purified.

15

D. Plasmid pDG160 is digested with *Hind* III and *Bam* HI and treated with calf intestinal alkaline phosphatase (CIAP) to remove the 5' phosphate and prevent religation and reconstruction of the vector. Alternatively, the digested vector fragment is gel purified.

E. The isolated fragments from steps B and C are combined with the digested pDG160 plasmid from step D in a 2:2:1 ratio at a concentration of 10-40 ng/μl of total DNA and ligated, resulting in a 8218 bp plasmid.

20

D. The ligation product is transformed into *E. coli* DG116 cells (described above) and transformant colonies which contain the desired plasmid, designated pTMA25, are identified by screening.

II. Mutagenesis I: D323A and E325A

Mutations in the DNA polymerase coding sequence of pTMA25 which result in the D323A and E325A amino acid mutations are made using site-specific primer-directed mutagenesis. For convenience in later manipulations, additional mutations are made which eliminate a *Bgl* II restriction enzyme cleavage site and create an *Spe* I restriction enzyme cleavage site. These additional mutations are made such that the encoded amino acid sequence is unchanged.

The following primers are used in the mutagenesis:

30

- Primer P1: mutagenic upstream primer corresponding to nucleotides 958-988 of SEQ ID NO: 9, with mutations as described in the table below.

- Primer P2: mutagenic downstream primer consisting of the reverse complement of primer P1.

- Primer P3: upstream primer corresponding to nucleotides 608-627 of SEQ ID NO: 9, which encompasses an *Xba* I site (nucleotides 621-626).

35

- Primer P4: downstream primer corresponding to nucleotides 1319-1339 of SEQ ID NO: 9, which encompasses part of a *Sac* I site (nucleotides 1318-1323).

The sequence of mutagenic upstream primer P1 consists of nucleotides 958-988 of the coding strand of SEQ ID NO: 9, except for the changes shown in the table below. The change in codon 323 (nucleotides 967-969) resulted in the elimination of a *Bgl* II site. The changes in codons 326 (nucleotides 966-978) and 327 (nucleotides 979-981) do not affect the sequence of the encoded amino acid, but results in the creation of a *Spe* I site.

45

50

Mutations in the primer P1			
nucleotides	codon	nucleotide change	amino acid change
967-969	323	GAT -> GCT	D323A
973-975	325	GAG -> GCG	E325A
976-978	326	ACG -> ACT	none
979-981	327	TCT -> AGT	none

55

The mutagenesis is carried out as described below. All amplifications are carried out by PCR under conditions well known in the art. For example, amplifications may be carried out using the GeneAmp PCR Reagent Kit with AmpliTaq<sup>®</sup> DNA Polymerase (Perkin Elmer, Norwalk, CT).

A. A region of the coding sequence is amplified from purified pTMA25 using primers P3 and P2, and the resulting 381 bp amplified product is gel purified.

B. A region of the coding sequence is amplified from purified pTMA25 using primers P1 and P4, and the resulting 382 bp amplified product is gel purified.

C. The amplified products from steps A and B are combined, heat denatured at 95°C, annealed, and extended with DNA polymerase using standard techniques.

D. The annealed and extended duplex DNA from step C is re-amplified using primers P3 and P4, and the resulting 732 bp amplified product is gel purified.

E. The amplified DNA from step D is digested with *Xba* I and *Sac* I.

F. Plasmid pTMA25 is digested with *Xba* I and *Sac* I, and treated with calf intestinal alkaline phosphatase (CIAP) to remove the 5' phosphate and prevent religation and reconstruction of the vector.

G. The digested DNA from step E is combined with the digested plasmid from step F in a 3:1 ratio and ligated.

H. The ligation product is transformed into *E. coli* DG116 cells and transformant colonies which contain the desired plasmid, designated pTMA30, are identified by screening.

### III. Sub-cloning II

The mutated gene coding sequence from pTMA30 is then subcloned into a pDG184 expression vector such that codons 1-283 are deleted. Nucleotide position numbers used herein refer to the position within the plasmid, wherein position 1 is defined by the *Eco* RI site upstream of the  $P_L$  promoter. The sub-cloning is carried out as follows:

A. Plasmid pTMA30, a 8218 bp plasmid, is digested with *Mlu* I, which cuts at nucleotide position 4443; *Bsp* HI, which cuts at positions 1210, 4761, 5769, and 5874; and *Afl* II, which cuts at position 7827. The *Afl* II digestion is carried out to further degrade a 3554 bp *Bsp* HI/*Bsp* HI fragment, which is similar in size to the desired 3233 bp *Bsp* HI/*Mlu* I fragment, in order to facilitate isolation of the desired fragment. The digestion yields six fragments, with lengths of 3233, 1952, 1601, 1103, 318, and 105 bp. The 3233 bp *Bsp* HI/*Mlu* I fragment corresponding to nucleotides 1211-4443 of the plasmid is isolated by gel electrophoresis.

B. Plasmid pDG184, a 5474 bp plasmid, is digested with *Mlu* I, which cuts at position 1699, and *Nco* I, which cuts at position 284. The digested fragments are treated with calf intestinal alkaline phosphatase (CIAP) to remove the 5' phosphate and prevent religation and reconstruction of the vector. Alternatively, the 4059 bp fragment is isolated by gel electrophoresis.

C. The isolated fragment from step A is combined with the digested pDG184 plasmid from step B in a 1:1 ratio at a concentration of 10-40 ng/ $\mu$ l of total DNA and ligated, resulting in a 7292 bp plasmid.

D. The ligation product is transformed into *E. coli* DG116 cells and transformant colonies which contain the desired plasmid, designated pTMA31, are identified by screening.

### IV. Mutagenesis II: F730Y

Additional mutations in the DNA polymerase coding sequence of pTMA31 which resulted in the F730Y mutation in the encoded amino acid sequence mutations were made using site-specific primer-directed mutagenesis. The mutagenesis was carried out using methods analogous to those described above.

The following primers were used in the mutagenesis.

- Primer FR1: mutagenic upstream primer corresponding to nucleotides 2173-2202 of SEQ ID NO: 9, with mutations as described in the table below.
- Primer FR2: mutagenic downstream primer essentially consisting of the reverse complement of primer FR1, but corresponding to nucleotides 2172-2200 of SEQ ID NO: 9.
- Primer FR3: upstream primer corresponding to nucleotides 1952-1972 of SEQ ID NO: 9, which lies upstream of a *Bst* XI site.
- Primer FR4: downstream primer corresponding to nucleotides 2415-2433 of SEQ ID NO: 9, which lies downstream of a *Xma* I site.

The sequence of mutagenic upstream primer FR1 consists of nucleotides 2173-2202 of the coding strand of SEQ ID NO: 9, except for the changes shown in the table below. The change in codons 729(2185-2187) does not affect the sequence of the encoded amino acid, but results in the creation of a *Hpa* I site.

Mutations in the primer FR1			
nucleotides	codon	nucleotide change	amino acid change
2185-2187	729	AAT -> AAC	none
2188-2190	730	TTT -> TAT	F730Y

The mutagenesis was carried out as described below.

A. A region of the coding sequence was amplified from purified pTMA31 using primers FR3 and FR2, and the resulting 249 bp amplified product was gel purified.

B. A region of the coding sequence was amplified from purified pTMA31 using primers FR1 and FR4, and the resulting 261 bp amplified product was gel purified.

C. The amplified products from steps A and B were combined, heat denatured at 95°C, annealed, and extended with DNA polymerase using standard techniques.

D. The annealed and extended duplex DNA from step C was re-amplified using primer FR3 and FR4, and the resulting 482 bp amplified product was extracted using a phenol/chloroform mixture and precipitated with EtOH.

E. The amplified DNA from step D was digested with *Bst* XI and *Xma* I, and the desired 337 bp DNA fragment was separated from smaller fragments using a CENTRICON 100 column (Amicon, Beverly, MA).

F. Plasmid pTMA31 was digested with *Bst* XI and *Xba* I.

G. The digested DNA from step E was combined with the digested plasmid from step F in a 3:1 ratio and ligated.

H. The ligation product was transformed into *E. coli* DG116 cells. Colonies were screened for the presence of the desired mutated plasmid by amplifying the plasmid DNA using primers FR3 and FR4, which amplify a region encompassing the unique *Hpa* I site introduced during the mutagenesis, digesting the amplified product with *Hpa* I, and analyzing the digestion product by gel electrophoresis. A colony containing the desired plasmid, designated pTMA31[F730Y], was selected and the gene sequence was confirmed by DNA sequencing.

The resulting expression system expresses a DNA polymerase, designated F730Y7ma31 DNA Polymerase, that consists of amino acids 284-893 of *Tma* DNA polymerase, mutated with the D323A, E325A, and F730Y mutations.

#### V Sub-cloning III

A fragment of the mutated coding sequence from pTMA31[F730Y] containing the F730Y mutation was subcloned into pTMA30 to replace the corresponding unmutated fragment, resulting in plasmid pTMA30[F730Y]. Nucleotide position numbers used herein refer to the position within the plasmid, wherein position 1 is defined by the *Eco* RI site upstream of the  $\lambda$  P<sub>L</sub> promoter. The sub-cloning was carried out as follows.

A. Plasmid pTMA31[F730Y], a 7292 bp plasmid, was digested with *Mlu* I, which cuts at nucleotide position 3517, and *Spe* I, which cuts at position 412. The 3105 bp *Mlu* I/*Spe* I fragment corresponding to nucleotides 413 to 3517 of the plasmid was isolated by gel electrophoresis.

B. Plasmid pTMA30, a 8218 bp plasmid, is digested with *Mlu* I, which cuts at nucleotide position 4443, and *Spe* I, which cuts at position 1338. The 5113 bp *Mlu* I/*Spe* I fragment corresponding to nucleotides 4444-1338 of the plasmid fragment was isolated by gel electrophoresis.

C. The isolated fragment from step A is combined with the isolated fragment from step B in a 1:1 ratio at a concentration of 10-40 ng/ $\mu$ l of total DNA and ligated.

D. The ligation product was transformed into *E. coli* DG116 cells. Colonies were screened for the presence of the desired 8.2 kb plasmid by amplifying the plasmid DNA using primers which amplify regions encompassing the unique *Hpa* I and *Spe* I sites introduced during the mutageneses, digesting the amplified products with *Hpa* I or *Spe* I, and analyzing the digestion products by gel electrophoresis. Plasmid DNA was prepared from colonies that contained plasmids which exhibited the expected digestion pattern in the screen, and was further analyzed by digestion with *Hpa* I, *Spe* I, and *Mlu* I followed by gel analysis of the digested DNA. A colony containing the desired plasmid, designated pTMA30[F730Y], was selected and the gene sequence was confirmed by DNA sequencing.

The resulting expression plasmid, pTMA30[F730Y], is under the control of the bacteriophage  $\lambda$  P<sub>L</sub> promoter and gene N ribosome binding site, and a Positive Retroregulatory Element (PRE, transcription terminator) from the *Bacillus*

*thuringiensis* delta-toxin gene. The plasmid also carries a mutated RNA II gene which renders the plasmid temperature sensitive for copy number and an ampicillin resistance gene.

## Example 2

### Expression of the recombinant DNA polymerase

This example describes the expression and purification of F730Y *Tma30* DNA Polymerase using an expression system, *E. coli* K12 strain DG116 cells harboring plasmid pTMA30[F730Y], essentially as described in example 1.

Initial growth of the expression system cells was carried out in a seed flask. Large scale fermentation was carried out in a 10 liter fermentation flask inoculated with the seed culture. The media and protocols used were as follows.

The seed medium consisted of 1X Bonner-Vogel salts (9.6 mM citric acid, 57 mM  $K_2HPO_4$ , 16.8 mM  $NaNH_4HPO_4$ , 0.8 mM  $MgSO_4$ ), + 25 mM  $(NH_4)_2SO_4$ , 2 mM  $MgSO_4$ , 10  $\mu$ g/ml thiamine-HCl, 0.2% glucose, 0.25% casamino acids, and 100  $\mu$ g/ml ampicillin and methicillin. The medium was formulated from sterile stock solutions, then filter-sterilized prior to use.

The fermentation medium consisted of 1X Bonner-Vogel salts (9.6 mM citric acid, 57 mM  $K_2HPO_4$ , 16.8 mM  $NaNH_4HPO_4$ , 0.8 mM  $MgSO_4$ ), + 25 mM  $(NH_4)_2SO_4$ , 2 mM  $MgSO_4$ , 10  $\mu$ M  $MnSO_4$ , 6.9  $\mu$ M  $ZnCl_2$ , 8.4  $\mu$ M  $CoCl_2$ , 8.3  $\mu$ M  $NaMoO_4$ , 6.8  $\mu$ M  $CaCl_2$ , 7.4  $\mu$ M  $CuCl_2$ , 8.1  $\mu$ M  $H_3BO_3$ , 1  $\mu$ M  $FeCl_3$ , 0.5 ml/l Macoll P2000 antifoam, 10  $\mu$ g/ml thiamine-HCl, 1.6% glucose, 2.0% casamino acids, and 100  $\mu$ g/ml ampicillin. The above ingredients (through the antifoam) were sterilized *in situ* at 121°C for 20 minutes, and the rest added from sterile, stock solutions, just prior to inoculation.

The seed culture was grown in a 100 ml flask of seed medium inoculated with 0.1 ml of frozen expression system cells. Following inoculation, the culture was shaken overnight at 30°C. The entire flask culture was used to inoculate a 10 liter fermentor culture.

Fermentation was carried out as follows. The initial temperature was 30°C, the pH was controlled at 6.9+/-0.1 with 4N  $NH_4OH$  and glacial acetic acid, and the dissolved oxygen controlled at 30% by adjusting the agitation rate as needed from an initial, minimum value of 300 rpm. The aeration rate was held constant at 5 liters per minute. When the culture reached 2.5 OD (680 nm), after about 6-7.5 hours, the temperature was shifted to 38.5°C to induce synthesis of the DNA polymerase using a ramp rate of 0.40°C/minute. The fermentation was allowed to continue overnight, to a total run time of about 24 hours. Cell paste was harvested by cross-flow filtration and centrifugation, and frozen at -20°C.

## Example 3

### Purification of the recombinant DNA polymerase

This example describes the purification of the expressed F730Y *Tma30* DNA Polymerase from the fermentation described above. The purification was carried out essentially as described in Lawyer *et al.*, 1993, PCR Method and Applications 2:275-287, with modifications as described below.

The following standard abbreviations are used.

PEI = polyethylenimine

TLCK = N- $\alpha$ -p-tosyl-L-lysine chloromethyl ketone-HCl

PEI is available commercially from, among others, Polysciences, Inc. (Warrington, PA).

TLCK is available commercially from, among others, Sigma Chemical Co. (St. Louis, MO).

Approximately 150 grams of frozen (-70°C) cells from the fermentation were thawed in lysis buffer (50 mM Tris-HCl, pH 7.5) containing 10 mM EDTA, 1 mM dithiothreitol (DTT), 2 mM Pefabloc SC (CenterChem, Inc., Stamford, CT); 1  $\mu$ g/ml Leupeptin (Boehringer Mannheim, Indianapolis, IN), and 1 mM TLCK. The cells were lysed by passage five times through a Microfluidizer at 10,000 psi. The lysate was diluted with lysis buffer to a final volume of 5.5X cell wet weight. The resulting lysate was designated Fraction I.

Ammonium sulfate was gradually added to the Fraction I lysate to a concentration of 0.2 M. Fraction I then was PEI-precipitated as follows.

PEI titrations were used to determine the minimum amount of PEI necessary to precipitate nucleic acids. Ten  $\mu$ l of each trial precipitation were added to 100  $\mu$ l of 0.5  $\mu$ g/ml Ethidium Bromide in a standard microwell plate. Standards consisted of appropriately diluted lysate containing no PEI. The plate was illuminated with UV light, and the concentration of PEI needed to remove at least 99% of the nucleic acid was determined.

PEI was added slowly with stirring to 0.4% (concentration as determined from the titrations). The PEI treated lysate

was centrifuged in a JA-10 rotor (500 ml bottles) at 8,000 RPM (11,300 x g) for 30 minutes at 5°C. The supernatant (Fraction II) was decanted and retained.

Ammonium sulfate was added to the Fraction II supernatant to a concentration of 0.4 M. Fraction II then was heat-treated as follows.

The heat treatment was carried out in a 3 liter Braun fermentor. The agitation rate was 250 rpm. The temperature was increased to 75° C over 6 minutes, held for 15 minutes, then cooled in the fermentor to 30° C as rapidly as possible. The heat-treated Fraction II supernatant from the PEI precipitation was removed from the fermentor and held on ice for at least 30 minutes, then centrifuged as described above. The supernatant (Fraction III) was decanted and retained.

Fraction III was subjected to phenyl sepharose column chromatography as follows. A 250 ml radial flow column (Sepragen Corp., Hayward, CA) was packed with Phenyl Sepharose Fast Flow (High Sub) (Pharmacia, Piscataway, NJ). Fraction III was diluted with 50 mM Tris (pH 7.5), 10 mM EDTA to reduce the ammonium sulfate to 0.3 M and then applied to the column. The column was washed (flow rate of 50 ml/minute) for 15-20 minutes (3-4 column volumes) in each of the following 4 buffers: (1) 50 mM Tris, pH 7.5, 10 mM EDTA, 0.3 M ammonium sulfate, 1 mM DTT; (2) 25 mM Tris, pH 7.5, 1 mM EDTA, 1 mM DTT; (3) 25 mM Tris, pH 7.5, 1 mM EDTA, 20% v/v ethylene glycol, 1 mM DTT; and (4) 25 mM Tris, pH 7.5, 1 mM EDTA, 20% v/v ethylene glycol, 1 mM DTT, 2.0 M urea. The urea eluate containing the DNA polymerase (Fraction IV) was collected as a single pool from approximately 3 to 18 minutes of the urea elution. The entire phenyl sepharose column step was completed in under 2 hours.

Fraction IV was subjected to heparin sepharose column chromatography as follows. Fraction IV (about 750 ml) was made 0.05 M in KCl (from a 3 M stock) and then loaded onto a 100 ml radial flow heparin sepharose column, which had been equilibrated in 25 mM Tris, pH 7.5, 1 mM EDTA, 0.05 M KCl, 1 mM DTT. After the load, the column was washed (flow rate of 20 ml/minute) for 30 minutes in equilibration buffer, then in 25 mM Tris, pH 7.5, 1 mM EDTA, 0.10 M KCl, 1 mM DTT. Finally the DNA polymerase was eluted in a 12 column volume gradient in 25 mM Tris, pH 7.5, 1 mM EDTA, and 0.10 to 0.5 M KCl, 1 mM DTT, collecting 75 fractions of 16 ml each. The heparin sepharose column step was completed in less than 3 hours. Fractions were analyzed by SDS-PAGE and some early fractions containing DNA polymerase that are less pure were removed from the pool (Fraction V).

Fraction V was concentrated to 20 ml on an Amicon YM30 membrane (Amicon Inc., Beverly, MA). The concentrate was dialyzed overnight at 4°C against 3X storage buffer (60 mM Tris, pH 8.0, 0.3 mM EDTA, 0.3 mM KCl, 3 mM DTT). Glycerol was added to the dialysate to a final concentration of 50 % (v/v) from an 80% (v/v) stock. Tween 20™ was added was added to a final concentration of 0.2% (w/v) from a 10% (w/v) stock. Sterile water was added to bring the volume of the preparation to 3 times the volume of the original lysate, yielding Fraction VI, a storage-stable preparation of F730Y *Tma30* DNA Polymerase.

Fraction VI was assayed for DNA polymerase activity essentially as described in Lawyer *et al.*, 1989, *J. Biol. Chem.* 264:6427, incorporated herein by reference.

#### Example 4

##### Extension Rate

The extension rate of the F730Y *Tma30* DNA Polymerase was measured using a template-limited primer extension assay. The assay was carried out using an excess of DNA polymerase, under which conditions the rate of extension is independent of the DNA polymerase concentration.

The chimeric enzyme of the present invention, F730Y *Tma30* DNA Polymerase, was compared to F730Y *Tma31* DNA Polymerase, expressed from plasmid pTMA31[F730Y], described above. F730Y *Tma31* DNA Polymerase is a mutated version of UI<sup>TM</sup> DNA Polymerase (Perkin Elmer, Norwalk, CT) that incorporates the D323A and E325A mutations which inactivate the 3' to 5' exonuclease activity, and the F730Y mutation. F730Y *Tma30* DNA Polymerase and F731Y *Tma31* DNA Polymerase differ primarily in that F730Y *Tma30* DNA Polymerase contains the 5'-nuclease domain from *Taq* DNA polymerase which has been mutated to inactivate the 5'-nuclease activity, whereas F730Y *Tma31* DNA Polymerase is missing the first 283 amino acids of *Tma* DNA polymerase. Accordingly, F730Y *Tma31* DNA Polymerase lacks 5'-nuclease activity as a result of a deletion of most of the 5'-nuclease domain.

DNA polymerase preparations first were assayed as described in Lawyer *et al.*, 1989, *J. Biol. Chem.* 264:6427, to determine the unit concentration and to determine an amount of enzyme needed such that the enzyme would be in excess. Based on these assays, it was determined that the use of 1 unit of F730Y *Tma30* DNA Polymerase or 3.5 units of F730Y *Tma31* DNA Polymerase in the extension rate assay described below was sufficient to insure that the extension rate would be independent of enzyme concentration. The definition of a unit of enzyme is as defined in Lawyer *et al.*, 1989, *supra*.

Extension rate was assayed for 3 minutes at 75°C in a 50 µl reaction mixture containing 5 µl of DNA polymerase (diluted as described in Lawyer *et al.*, 1989, *supra*, to contain the unit amount described above) and 45 µl of a reaction buffer containing 50 mM Bicine, pH 8.3, 25°C; 2.5 mM MgCl<sub>2</sub>; 1 mM β-mercaptoethanol; 200 µM each of dATP, dGTP

and dTTP; 100  $\mu$ M [ $\alpha$ - $^{33}$ P]dCTP (0.8  $\mu$ Ci/reaction); and 0.075 pmoles of the M13mp18 (Perkin Elmer, Norwalk, CT) template DNA preannealed to primer DG48, (SEQ ID NO: 11; 5'-GGGAAGGGCGATCGGTGCGGGCCTCTTCGC). The reactions were stopped by the addition of 10  $\mu$ l 60 mM EDTA and stored at 0°C.

A 25  $\mu$ l portion of the stopped reaction was diluted with 1 ml of 2 mM EDTA with 50  $\mu$ g/ml sheared salmon sperm DNA as a carrier. The DNA was precipitated by the addition of 1 ml 20% trichloroacetic acid (w/v) and 2% sodium pyrophosphate, and incubated at 0°C for 15 minutes. Precipitated DNA was collected on GF/C filter discs (Whatman International Ltd., Maidstone, England) and washed extensively with 5% trichloroacetic acid and 2% sodium pyrophosphate, then with 5% trichloroacetic acid, then with 5 ml of 95% ethanol, dried, and counted.

The amount of [ $\alpha$ - $^{33}$ P]dCMP incorporated per minute was determined for each sample. The data shown below represent the average of two reactions.

DNA Polymerase	CPM
F730Y <i>Tma</i> 30	1575
F730Y <i>Tma</i> 31	1116
Ratio	1.41

The data indicate that, as measured by the above assay, F730Y *Tma*30 DNA Polymerase has a 41% greater extension rate than F730Y *Tma*31 DNA Polymerase. In view of the difference between the two enzymes, the data indicate that the presence in F730Y *Tma*30 DNA Polymerase of the 5'-nuclease domain from *Taq* DNA polymerase, although inactivated by the G46D mutation, results in a significantly higher extension rate.

The extension products from a series of time points were analyzed further by denaturing agarose gel electrophoresis, which confirmed that the results represent an increase in the extension rate of the enzyme.

#### Example 5

##### Dye Terminator Cycle Sequencing

This example demonstrates the application of the F730Y *Tma*30 DNA Polymerase to dye-labeled, dideoxy-terminator cycle sequencing. For comparison, cycle sequencing reactions also were carried out using AmpliTaq<sup>®</sup> DNA Polymerase, FS, a mutant form of *Taq* DNA polymerase that lacks exonuclease activity and incorporates an F667Y mutation, which is analogous to the F730Y mutation in F730Y *Tma*30 DNA Polymerase.

Cycle sequencing reactions were carried out using the reagents and protocols of the ABI PRISM<sup>™</sup> Dye Terminator Cycle Sequencing Core Kit with AmpliTaq<sup>®</sup> DNA Polymerase FS (Perkin Elmer, Norwalk, CT). The separate packaging of the reagents in this kit allowed for easy substitution of F730Y *Tma*30 DNA polymerase for AmpliTaq<sup>®</sup> DNA Polymerase FS. In the kit, the AmpliTaq<sup>®</sup> DNA Polymerase FS is provided combined with *rTth* Thermostable Inorganic Pyrophosphatase. For reactions using F730Y *Tma*30 DNA Polymerase, the DNA polymerase/pyrophosphatase mixture of the kit was replaced with 10 units of F730Y *Tma*30 DNA Polymerase and 20 units of *rTth* Thermostable Inorganic Pyrophosphatase. *rTth* Thermostable Inorganic Pyrophosphatase is described in copending U.S. Patent No. 5,665,551, incorporated herein by reference.

The positive control template, pGEM<sup>®</sup>-3Zf(+) and primer, -21 M13, supplied with the kit were used. Reactions were carried out in a GeneAmp<sup>®</sup> PCR System 9600 thermal cycler (Perkin-Elmer, Norwalk, CT) using the recommended thermal cycling protocol (25 cycles: 96°C for 10 seconds; 50°C for 5 second; and 60°C for 4 minutes).

Extension products were purified of unincorporated dye terminators by spin column purification using a Centri-Sep<sup>™</sup> column from Princeton Separations (Adelphia, NJ) and dried in a vacuum centriuge, as recommended in the protocol. Samples were resuspended in 6  $\mu$ l of loading buffer (deionized formamide and 25 mM EDTA (pH 8.0) containing 50 mg/l Blue dextran in a ratio of 5:1 formamide to EDTA/Blue dextran). The samples were vortexed, spun, heated to 90°C for 3 minutes to denature, and then directly loaded onto a pre-electrophoresed 48 cm (well-to-read) 4% polyacrylamide/6 M urea gel and electrophoresed and analyzed on an ABI PRISM<sup>™</sup> 377 DNA Sequencer (Perkin Elmer, Norwalk, CT) according to the manufacturer's instructions.

The resulting sequencing traces are shown in the figures. Figures 2A, 2B, and 2C provide a sequencing trace from a cycle sequencing reaction using F730Y *Tma*30 DNA Polymerase, and Figures 3A, 3B, and 3C provide sequencing trace from a cycle sequencing reaction using AmpliTaq<sup>®</sup> DNA Polymerase, FS. The base calling was set to begin with the tenth nucleotide from the primer.

It is clear from a comparison of the sequence tracings that the use of F730Y *Tma*30 DNA Polymerase results in a

significant improvement in the overall uniformity of peak heights when compared to the results obtained using AmpliTaq® DNA Polymerase FS. In particular, the use of F730Y *Tma*30 DNA Polymerase significantly increases the peak heights of those bases which, because of the DNA sequence context, result in very low peak heights when AmpliTaq® DNA Polymerase FS is used, such as G after A or C, A after A or C, and T after T. Similarly, the use of F730Y *Tma*30 DNA Polymerase significantly decreases the peak height of those bases which, because of the DNA sequence context, result in very high peak heights when AmpliTaq® DNA Polymerase FS is used, such as A after G. The uniformity of peak heights contributes to an increase in the accuracy of the sequencing.

The accuracy of the sequencing, i.e., the fraction of bases correctly sequenced, averaged for two duplicated reactions, was calculated from the results of the automated base-calling by the ABI PRISM™ 377 DNA Sequencing System analysis software. The results are summarized in the table, below. Typically, sequencing errors are most prevalent in the region next to the primer and the terminal regions away from the primer. Consequently, the first 10 nucleotides following the primer were ignored and the accuracy was calculated separately for the subsequent 50 nucleotides, the next 500 nucleotides, and finally two terminal regions, each 100 nucleotides in length.

Comparison of Sequencing Accuracy				
	nucleotide position:			
	11-60	61-560	561-660	661-760
F730YTma DNA Polymerase	95%	100%	100%	97.5%
AmpliTa <sup>®</sup> DNA Polymerase FS	97%	99%	97%	88.5%

The results demonstrate that F730Y *Tma*30 DNA Polymerase provides a substantial improvement in sequencing accuracy; strikingly so at longer read lengths (> 560 nucleotides). The use of F730Y *Tma*30 DNA Polymerase completely eliminated errors in the 500 nucleotide region from nucleotides 51-550 and the first terminal region from nucleotides 551-650. Furthermore, the use of F730Y *Tma*30 DNA Polymerase extended the length of target sequenceable with an accuracy of at least 97% by at least 100 nucleotides, from 650 nucleotides using AmpliTaq® DNA Polymerase FS, to at least 750 nucleotides using F730Y *Tma*30 DNA Polymerase.

#### Example 6

#### Dye Primer Cycle Sequencing

This example demonstrates the application of the DNA polymerase of the invention to dye primer sequencing. Cycle sequencing reactions are performed in a buffer consisting of 25 mM Tris-HCl (pH 9.1) and 3.5 mM MgCl<sub>2</sub>. Four individual reactions, one for each of the four dideoxy terminators, are performed. Reaction conditions for each of the four reactions are described below:

##### 1. Dideoxy-ATP reactions (5 µl):

100 µM each dATP, dCTP, and dTTP (Perkin-Elmer),  
 100 µM c7dGTP (Pharmacia, Piscataway, NJ),  
 0.5 µM ddATP (Pharmacia),  
 0.1 µg M13mp 18 single-strand DNA template (Perkin-Elmer),  
 0.4 pmol JOE Dye Primer (Perkin-Elmer),  
 1 unit DNA polymerase, and  
 5 units of *rTth* Thermostable Inorganic Pyrophosphatase.

##### 2. Dideoxy-CTP reactions (5 µl):

100 µM each dATP, dCTP, and dTTP (Perkin-Elmer),  
 100 µM c7dGTP (Pharmacia),  
 0.5 µM ddCTP (Pharmacia),  
 0.1 µg M13mp18 single-strand DNA template (Perkin-Elmer),  
 0.4 pmol FAM Dye Primer (Perkin-Elmer),

1 unit DNA polymerase, and  
5 units of *rTth* Thermostable Inorganic Pyrophosphatase.

### 3. Dideoxy-GTP reactions (10 $\mu$ l):

100  $\mu$ M each dATP, dCTP, and dTTP (Perkin-Elmer),  
100  $\mu$ M c7dGTP (Pharmacia),  
0.5  $\mu$ M ddGTP (Pharmacia),  
0.2  $\mu$ g M13mp 18 single-strand DNA template (Perkin-Elmer),  
0.8 pmol TAMRA Dye Primer (Perkin-Elmer),  
2 units DNA polymerase, and  
10 units of *rTth* Thermostable Inorganic Pyrophosphatase.

### 4. Dideoxy-TTP reactions (10 $\mu$ l):

100  $\mu$ M each dATP, dCTP, and dTTP (Perkin-Elmer),  
100  $\mu$ M c7dGTP (Pharmacia),  
0.5  $\mu$ M ddTTP (Pharmacia),  
0.2  $\mu$ g M13mp18 single-strand DNA template (Perkin-Elmer),  
0.8 pmol ROX Dye Primer (Perkin-Elmer),  
2 units DNA polymerase, and  
10 units of *rTth* Thermostable Inorganic Pyrophosphatase.

Each of the four reactions are placed in a preheated (75°C) Perkin-Elmer GeneAmp® PCR System 9600 thermal  
cyclor and subjected to 15 cycles of 96°C for 15 seconds, 55°C for 1 second, and 70°C for 1 minute, followed by 15  
cycles of 96°C for 15 seconds and 70°C for 1 minute. The four reactions are pooled and precipitated by the addition of  
100  $\mu$ l 95% ethanol and 2.0  $\mu$ l 3 M sodium acetate (pH 5.3) at 4°C for 15 minutes. The pooled reaction is microcentri-  
fuged for 15 minutes to collect precipitate, the supernatant is removed, and the pellet dried. The pellet is resuspended  
in 6  $\mu$ l of deionized formamide/50 mM EDTA (pH 8.0)/5/1 (v/v), heated at 90°C for 2 minutes, and directly loaded onto a  
pre-electrophoresed 4% polyacrylamide/6 M urea gel and electrophoresed and analyzed on an ABI PRISM™ 377 DNA  
Sequencer (Perkin Elmer, Norwalk, CT) according to the manufacturer instructions.

## Example 7

### Effect of Pyrophosphatase

In the dye-terminator reactions described in Example 5, above, 20 units of *rTth* Thermostable Inorganic Pyrophos-  
phatase (PPase) were added to the reaction to reduce the effects of pyrophosphorolysis. This amount of PPase had  
been determined to be beneficial for reactions using AmpliTaq® DNA Polymerase FS. The following experiments were  
carried out to determine the effect of PPase concentration on the results of cycle sequencing reactions using  
F730Y *Tma30* DNA Polymerase.

Dye-terminator cycle sequencing reactions were carried out essentially as described in Example 5, above, with the  
exception that the PPase concentration was varied between reactions. PPase concentrations of 0, 0.5, 1, and 20 units  
per reaction were tested. The target DNA, pGEM-3Zf(+), and the primer used, M13(-21), were from the ABI PRISM™  
Dye Terminator Cycle Sequencing Core Kit, from Perkin Elmer (Norwalk, CT). All reactions were done in duplicate.

The results of each sequencing reaction were compared by direct comparison of the sequencing traces. The  
results revealed no obvious differences between the four PPase concentrations. Sequencing trace peak heights and  
background were comparable to a read of at least 500 base pairs. Thus, the data indicate that the use of F730Y *Tma30*  
DNA Polymerase allows cycle sequencing reactions to be carried out without added PPase.

## Example 8

### Optimal dITP Concentration

The ABI PRISM™ Dye Terminator Cycle Sequencing Core Kit with AmpliTaq® DNA Polymerase FS (Perkin Elmer,  
Norwalk, CT), used in Example 5, above, provides a dNTP mix containing dITP, dATP, dCTP, and dTTP in a 5:1:1:1 ratio.  
The increased concentration of dITP compensates for the lower dITP incorporation efficiency possessed by AmpliTaq®  
DNA Polymerase FS. An analysis of the strength of the G signal peaks generated in the cycle sequencing reactions



described in Example 5 suggested that F730Y *Tma30* DNA Polymerase incorporates dITP with greater efficiency and, consequently, the dITP concentration should be decreased. Further reactions were carried out to determine an optimal concentration of dITP for use in dye-terminator cycle sequencing reactions using F730Y *Tma30* DNA Polymerase.

Reactions were carried out essentially as described in Example 5, using the ABI PRISM™ Dye Terminator Cycle Sequencing Core Kit with AmpliTaq® DNA Polymerase FS. In place of the dNTP mix provided with the kit, dNTP mixes containing 100 µM each dATP, dCTP, and dTTP, and a range of dITP concentrations in a TE buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA) were used. As described in Example 5, a F730Y *Tma30* DNA Polymerase/*rTth* Thermostable Inorganic Pyrophosphatase mixture was substituted for the AmpliTaq® DNA Polymerase FS/*rTth* Thermostable Inorganic Pyrophosphatase mixture provided with the kit.

The optimal dITP concentration was determined by comparisons of both the sequence traces and the unprocessed signal strength data. Based on these experiments, it was determined that the dITP concentration is preferably lowered to 150-250 µM. The results indicate that F730Y *Tma30* DNA Polymerase incorporates dITP significantly more efficiently than does AmpliTaq® DNA Polymerase FS. Further experiments carried out comparing F730Y *Tma30* DNA Polymerase to other

thermostable DNA polymerases (results not shown) also indicated that F730Y *Tma30* DNA Polymerase possesses a significantly increased efficiency of dITP incorporation relative to other thermostable DNA polymerases.

#### Deposits

The following deposit was made on the date given:

Strain	ATCC No.	Deposit Date
pUC18:Tma25	98443	May 28, 1997

This deposit was made by ROCHE MOLECULAR SYSTEMS, Inc., 1145 Atlantic Avenue, Alameda, California 94501, U.S.A., at the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, MD 20852, U.S.A. under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure and the Regulations thereunder (Budapest Treaty). This assures maintenance of a viable culture for 30 years from date of deposit. The organism will be made available by ATCC under the terms of the Budapest Treaty, and subject to an agreement between applicants and ATCC, which assures permanent and unrestricted availability of the progeny of the cultures to the public upon issuance of the pertinent U.S. patent or upon laying open to the public of any U.S. or foreign patent application, whichever comes first, and assures availability of the progeny to one determined by the U.S. Commissioner of Patents and Trademarks to be entitled thereto according to 35 U.S.C. §122 and the Commissioner's rules pursuant thereto (including 37 C.F.R. §1.14 with particular reference to 886 OG 638). The assignee of the present application agrees that if the culture on deposit should die or be lost or destroyed when cultivated under suitable conditions, it will be promptly replaced on notification with a viable specimen of the same culture. Availability of the deposited strain is not to be construed as a license to practice the invention in contravention of the rights granted under the authority of any government in accordance with its patent laws.

ROCHE MOLECULAR SYSTEMS, Inc., 1145 Atlantic Avenue, Alameda, California 94501, U.S.A has authorized F. HOFFMANN-LA ROCHE AG, 124 Grenzacherstrasse, CH-4070 Basle, Switzerland, to refer to the aforementioned deposited biological material in foreign patent applications claiming priority from U.S. Patent Application Ser. No. 60-023376 and has given the unreserved and irrevocable consent that the deposited material is made available to the public.

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

## (i) APPLICANT:

(A) NAME: F.Hoffmann-La Roche Ltd  
 (B) STREET: Grenzacherstrasse 124  
 (C) CITY: Basel  
 (D) STATE: BS  
 (E) COUNTRY: Switzerland  
 (F) POSTAL CODE (ZIP): CH-4070  
 (G) TELEPHONE: (0)61 688 24 03  
 (H) TELEFAX: (0)61 688 13 35  
 (I) TELEX: 962292/965512 hlr ch

(ii) TITLE OF INVENTION: Mutant chimeric RNA polymerases

(iii) NUMBER OF SEQUENCES: 11

## (iv) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk  
 (B) COMPUTER: IBM PC compatible  
 (C) OPERATING SYSTEM: PC-DOS/MS-DOS  
 (D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

## (vi) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: US 60/052,065  
 (B) FILING DATE: 09-JUL-1997

## (2) INFORMATION FOR SEQ ID NO:1:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 291 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Met Ala Arg Leu Phe Leu Phe Asp Gly Thr Ala Leu Ala Tyr Arg Ala  
 1 5 10 15  
 Tyr Tyr Ala Leu Asp Arg Ser Leu Ser Thr Ser Thr Gly Ile Pro Thr  
 20 25 30  
 Asn Ala Thr Tyr Gly Val Ala Arg Met Leu Val Arg Phe Ile Lys Asp  
 35 40 45  
 His Ile Ile Val Gly Lys Asp Tyr Val Ala Val Ala Phe Asp Lys Lys  
 50 55 60  
 Ala Ala Thr Phe Arg His Lys Leu Leu Glu Thr Tyr Lys Ala Gln Arg  
 65 70 75 80  
 Pro Lys Thr Pro Asp Leu Leu Ile Gln Gln Leu Pro Tyr Ile Lys Lys  
 85 90 95  
 Leu Val Glu Ala Leu Gly Met Lys Val Leu Glu Val Glu Gly Tyr Glu  
 100 105 110  
 Ala Asp Asp Ile Ile Ala Thr Leu Ala Val Lys Gly Leu Pro Leu Phe  
 115 120 125  
 Asp Glu Ile Phe Ile Val Thr Gly Asp Lys Asp Met Leu Gln Leu Val  
 130 135 140

Asn Glu Lys Ile Lys Val Trp Arg Ile Val Lys Gly Ile Ser Asp Leu  
 145 150 155 160  
 Glu Leu Tyr Asp Ala Gln Lys Val Lys Glu Lys Tyr Gly Val Glu Pro  
 165 170 175  
 Gln Gln Ile Pro Asp Leu Leu Ala Leu Thr Gly Asp Glu Ile Asp Asn  
 180 185 190  
 Ile Pro Gly Val Thr Gly Ile Gly Glu Lys Thr Ala Val Gln Leu Leu  
 195 200 205  
 Glu Lys Tyr Lys Asp Leu Glu Asp Ile Leu Asn His Val Arg Glu Leu  
 210 215 220  
 Pro Gln Lys Val Arg Lys Ala Leu Leu Arg Asp Arg Glu Asn Ala Ile  
 225 230 235 240  
 Leu Ser Lys Lys Leu Ala Ile Leu Glu Thr Asn Val Pro Ile Glu Ile  
 245 250 255  
 Asn Trp Glu Glu Leu Arg Tyr Gln Gly Tyr Asp Arg Glu Lys Leu Leu  
 260 265 270  
 Pro Leu Leu Lys Glu Leu Glu Phe Ala Ser Ile Met Lys Glu Leu Gln  
 275 280 285  
 Leu Tyr Glu  
 290

## (2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 289 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met Arg Gly Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val Leu Leu  
 1 5 10 15  
 Val Asp Gly His His Leu Ala Tyr Arg Thr Phe His Ala Leu Lys Gly  
 20 25 30  
 Leu Thr Thr Ser Arg Gly Glu Pro Val Gln Ala Val Tyr Gly Phe Ala  
 35 40 45  
 Lys Ser Leu Leu Lys Ala Leu Lys Glu Asp Gly Asp Ala Val Ile Val  
 50 55 60  
 Val Phe Asp Ala Lys Ala Pro Ser Phe Arg His Glu Ala Tyr Gly Gly  
 65 70 75 80  
 Tyr Lys Ala Gly Arg Ala Pro Thr Pro Glu Asp Phe Pro Arg Gln Leu  
 85 90 95  
 Ala Leu Ile Lys Glu Leu Val Asp Leu Leu Gly Leu Ala Arg Leu Glu  
 100 105 110  
 Val Pro Gly Tyr Glu Ala Asp Asp Val Leu Ala Ser Leu Ala Lys Lys  
 115 120 125  
 Ala Glu Lys Glu Gly Tyr Glu Val Arg Ile Leu Thr Ala Asp Lys Asp  
 130 135 140

Leu Tyr Gln Leu Leu Ser Asp Arg Ile His Val Leu His Pro Glu Gly  
 145 150 155 160  
 Tyr Leu Ile Thr Pro Ala Trp Leu Trp Glu Lys Tyr Gly Leu Arg Pro  
 165 170 175  
 Asp Gln Trp Ala Asp Tyr Arg Ala Leu Thr Gly Asp Glu Ser Asp Asn  
 180 185 190  
 Leu Pro Gly Val Lys Gly Ile Gly Glu Lys Thr Ala Arg Lys Leu Leu  
 195 200 205  
 Glu Glu Trp Gly Ser Leu Glu Ala Leu Leu Lys Asn Leu Asp Arg Leu  
 210 215 220  
 Lys Pro Ala Ile Arg Glu Lys Ile Leu Ala His Met Asp Asp Leu Lys  
 225 230 235 240  
 Leu Ser Trp Asp Leu Ala Lys Val Arg Thr Asp Leu Pro Leu Glu Val  
 245 250 255  
 Asp Phe Ala Lys Arg Arg Glu Pro Asp Arg Glu Arg Leu Arg Ala Phe  
 260 265 270  
 Leu Glu Arg Leu Glu Phe Gly Ser Leu Leu His Glu Phe Gly Leu Leu  
 275 280 285  
 Glu

## (2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 288 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Met Ala Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val Leu Leu Val  
 1 5 10 15  
 Asp Gly His His Leu Ala Tyr Arg Thr Phe Phe Ala Leu Lys Gly Leu  
 20 25 30  
 Thr Thr Ser Arg Gly Glu Pro Val Gln Ala Val Tyr Gly Phe Ala Lys  
 35 40 45  
 Ser Leu Leu Lys Ala Leu Lys Glu Asp Gly Asp Val Val Val Val Val  
 50 55 60  
 Phe Asp Ala Lys Ala Pro Ser Phe Arg His Glu Ala Tyr Glu Ala Tyr  
 65 70 75 80  
 Lys Ala Gly Arg Ala Pro Thr Pro Glu Asp Phe Pro Arg Gln Leu Ala  
 85 90 95  
 Leu Ile Lys Glu Leu Val Asp Leu Leu Gly Leu Val Arg Leu Glu Val  
 100 105 110  
 Pro Gly Phe Glu Ala Asp Asp Val Leu Ala Thr Leu Ala Lys Arg Ala  
 115 120 125  
 Glu Lys Glu Gly Tyr Glu Val Arg Ile Leu Thr Ala Asp Arg Asp Leu  
 130 135 140

Tyr Gln Leu Leu Ser Glu Arg Ile Ala Ile Leu His Pro Glu Gly Tyr  
 145 150 155 160  
 Leu Ile Thr Pro Ala Trp Leu Tyr Glu Lys Tyr Gly Leu Arg Pro Glu  
 165 170 175  
 Gln Trp Val Asp Tyr Arg Ala Leu Ala Gly Asp Pro Ser Asp Asn Ile  
 180 185 190  
 Pro Gly Val Lys Gly Ile Gly Glu Lys Thr Ala Gln Arg Leu Ile Arg  
 195 200 205  
 Glu Trp Gly Ser Leu Glu Asn Leu Phe Gln His Leu Asp Gln Val Lys  
 210 215 220  
 Pro Ser Leu Arg Glu Lys Leu Gln Ala Gly Met Glu Ala Leu Ala Leu  
 225 230 235 240  
 Ser Arg Lys Leu Ser Gln Val His Thr Asp Leu Pro Leu Glu Val Asp  
 245 250 255  
 Phe Gly Arg Arg Arg Thr Pro Asn Leu Glu Gly Leu Arg Ala Phe Leu  
 260 265 270  
 Glu Arg Leu Glu Phe Gly Ser Leu Leu His Glu Phe Gly Leu Leu Glu  
 275 280 285

## (2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 291 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Met Glu Ala Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val Leu Leu  
 1 5 10 15  
 Val Asp Gly His His Leu Ala Tyr Arg Thr Phe Phe Ala Leu Lys Gly  
 20 25 30  
 Leu Thr Thr Ser Arg Gly Glu Pro Val Gln Ala Val Tyr Gly Phe Ala  
 35 40 45  
 Lys Ser Leu Leu Lys Ala Leu Lys Glu Asp Gly Tyr Lys Ala Val Phe  
 50 55 60  
 Val Val Phe Asp Ala Lys Ala Pro Ser Phe Arg His Glu Ala Tyr Glu  
 65 70 75 80  
 Ala Tyr Lys Ala Gly Arg Ala Pro Thr Pro Glu Asp Phe Pro Arg Gln  
 85 90 95  
 Leu Ala Leu Ile Lys Glu Leu Val Asp Leu Leu Gly Phe Thr Arg Leu  
 100 105 110  
 Glu Val Pro Gly Tyr Glu Ala Asp Asp Val Leu Ala Thr Leu Ala Lys  
 115 120 125  
 Lys Ala Glu Lys Glu Gly Tyr Glu Val Arg Ile Leu Thr Ala Asp Arg  
 130 135 140  
 Asp Leu Tyr Gln Leu Val Ser Asp Arg Val Ala Val Leu His Pro Glu  
 145 150 155 160

Gly His Leu Ile Thr Pro Glu Trp Leu Trp Glu Lys Tyr Gly Leu Arg  
 155 170 175  
 Pro Glu Gln Trp Val Asp Phe Arg Ala Leu Val Gly Asp Pro Ser Asp  
 180 185 190  
 Asn Leu Pro Gly Val Lys Gly Ile Gly Glu Lys Thr Ala Leu Lys Leu  
 195 200 205  
 Leu Lys Glu Trp Gly Ser Leu Glu Asn Leu Leu Lys Asn Leu Asp Arg  
 210 215 220  
 Val Lys Pro Glu Asn Val Arg Glu Lys Ile Lys Ala His Leu Glu Asp  
 225 230 235 240  
 Leu Arg Leu Ser Leu Glu Leu Ser Arg Val Arg Thr Asp Leu Pro Leu  
 245 250 255  
 Glu Val Asp Leu Ala Gln Gly Arg Glu Pro Asp Arg Glu Gly Leu Arg  
 260 265 270  
 Ala Phe Leu Glu Arg Leu Glu Phe Gly Ser Leu Leu His Glu Phe Gly  
 275 280 285  
 Leu Leu Glu  
 290

## (2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 291 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Met Lys Ala Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val Leu Leu  
 1 5 10 15  
 Val Asp Gly His His Leu Ala Tyr Arg Thr Phe Phe Ala Leu Lys Gly  
 20 25 30  
 Leu Thr Thr Ser Arg Gly Glu Pro Val Gln Ala Val Tyr Gly Phe Ala  
 35 40 45  
 Lys Ser Leu Leu Lys Ala Leu Lys Glu Asp Gly Tyr Lys Ala Val Phe  
 50 55 60  
 Val Val Phe Asp Ala Lys Ala Pro Ser Phe Arg His Glu Ala Tyr Glu  
 65 70 75 80  
 Ala Tyr Lys Ala Gly Arg Ala Pro Thr Pro Glu Asp Phe Pro Pro Gln  
 85 90 95  
 Leu Ala Leu Ile Lys Glu Leu Val Asp Leu Leu Gly Phe Thr Arg Leu  
 100 105 110  
 Glu Val Pro Gly Phe Glu Ala Asp Asp Val Leu Ala Thr Leu Ala Lys  
 115 120 125  
 Lys Ala Glu Arg Glu Gly Tyr Glu Val Arg Ile Leu Thr Ala Asp Arg  
 130 135 140  
 Asp Leu Tyr Gln Leu Val Ser Asp Arg Val Ala Val Leu His Pro Glu  
 145 150 155 160

EP 0 892 058 A2

5 Gly His Leu Ile Thr Pro Glu Trp Leu Trp Glu Lys Tyr Gly Leu Lys  
165 170 175

Pro Glu Gln Trp Val Asp Phe Arg Ala Leu Val Gly Asp Pro Ser Asp  
180 185 190

Asn Leu Pro Gly Val Lys Gly Ile Gly Glu Lys Thr Ala Leu Lys Leu  
195 200 205

Leu Lys Glu Trp Gly Ser Leu Glu Asn Ile Leu Lys Asn Leu Asp Arg  
210 215 220

10 Val Lys Pro Glu Ser Val Arg Glu Arg Ile Lys Ala His Leu Glu Asp  
225 230 235 240

Leu Lys Leu Ser Leu Glu Leu Ser Arg Val Arg Ser Asp Leu Pro Leu  
245 250 255

15 Glu Val Asp Phe Ala Arg Arg Arg Glu Pro Asp Arg Glu Gly Leu Arg  
260 265 270

Ala Phe Leu Glu Arg Leu Glu Phe Gly Ser Leu Leu His Glu Phe Gly  
275 280 285

20 Leu Leu Glu  
290

(2) INFORMATION FOR SEQ ID NO:6:

25 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 291 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Met Glu Ala Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val Leu Leu  
1 5 10 15

35 Val Asp Gly His His Leu Ala Tyr Arg Thr Phe Phe Ala Leu Lys Gly  
20 25 30

Leu Thr Thr Ser Arg Gly Glu Pro Val Gln Ala Val Tyr Gly Phe Ala  
35 40 45

40 Lys Ser Leu Leu Lys Ala Leu Lys Glu Asp Gly Tyr Lys Ala Val Phe  
50 55 60

Val Val Phe Asp Ala Lys Ala Pro Ser Phe Arg His Glu Ala Tyr Glu  
65 70 75 80

Ala Tyr Lys Ala Gly Arg Ala Pro Thr Pro Glu Asp Phe Pro Arg Gln  
85 90 95

45 Leu Ala Leu Ile Lys Glu Leu Val Asp Leu Leu Gly Phe Thr Arg Leu  
100 105 110

Glu Val Pro Gly Tyr Glu Ala Asp Asp Val Leu Ala Thr Leu Ala Lys  
115 120 125

50 Asn Pro Glu Lys Glu Gly Tyr Glu Val Arg Ile Leu Thr Ala Asp Arg  
130 135 140

Asp Leu Asp Gln Leu Val Ser Asp Arg Val Ala Val Leu His Pro Glu  
145 150 155 160

55

EP 0 892 058 A2

5 Gly His Leu Ile Thr Pro Glu Trp Leu Trp Gln Lys Tyr Gly Leu Lys  
165 170 175

Pro Glu Gln Trp Val Asp Phe Arg Ala Leu Val Gly Asp Pro Ser Asp  
180 135 190

Asn Leu Pro Gly Val Lys Gly Ile Gly Glu Lys Thr Ala Leu Lys Leu  
195 200 205

Leu Lys Glu Trp Gly Ser Leu Glu Asn Leu Leu Lys Asn Leu Asp Arg  
210 215 220

10 Val Lys Pro Glu Asn Val Arg Glu Lys Ile Lys Ala His Leu Glu Asp  
225 230 235 240

Leu Arg Leu Ser Leu Glu Leu Ser Arg Val Arg Thr Asp Leu Pro Leu  
245 250 255

15 Glu Val Asp Leu Ala Gln Gly Arg Glu Pro Asp Arg Glu Gly Leu Arg  
260 265 270

Ala Phe Leu Glu Arg Leu Glu Phe Gly Ser Leu Leu His Glu Phe Gly  
275 280 285

20 Leu Leu Glu  
290

(2) INFORMATION FOR SEQ ID NO:7:

25 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 287 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val Leu Leu Val Asp Gly  
1 5 10 15

35 His His Leu Ala Tyr Arg Thr Phe Phe Ala Leu Lys Gly Leu Thr Thr  
20 25 30

Ser Arg Gly Glu Pro Val Gln Ala Val Tyr Gly Phe Ala Lys Ser Leu  
35 40 45

40 Leu Lys Ala Leu Lys Glu Asp Gly Glu Val Ala Ile Val Val Phe Asp  
50 55 60

Ala Lys Ala Pro Ser Phe Arg His Glu Ala Tyr Glu Ala Tyr Lys Ala  
65 70 75 80

Gly Arg Ala Pro Thr Pro Glu Asp Phe Pro Arg Gln Leu Ala Leu Ile  
85 90 95

45 Lys Glu Leu Val Asp Leu Leu Gly Leu Val Arg Leu Glu Val Pro Gly  
100 105 110

Phe Glu Ala Asp Asp Val Leu Ala Thr Leu Ala Lys Lys Ala Glu Arg  
115 120 125

50 Glu Gly Tyr Glu Val Arg Ile Leu Ser Ala Asp Arg Asp Leu Tyr Gln  
130 135 140

Leu Leu Ser Asp Arg Ile His Leu Leu His Pro Glu Gly Glu Val Leu  
145 150 155 160

55



Thr Pro Gly Trp Leu Gln Glu Arg Tyr Gly Leu Ser Pro Glu Arg Trp  
 165 170 175  
 Val Glu Tyr Arg Ala Leu Val Gly Asp Pro Ser Asp Asn Leu Pro Gly  
 180 185 190  
 Val Pro Gly Ile Gly Glu Lys Thr Ala Leu Lys Leu Leu Lys Glu Trp  
 195 200 205  
 Gly Ser Leu Glu Ala Ile Leu Lys Asn Leu Asp Gln Val Lys Pro Glu  
 210 215 220  
 Arg Val Arg Glu Ala Ile Arg Asn Asn Leu Asp Lys Leu Gln Met Ser  
 225 230 235 240  
 Leu Glu Leu Ser Arg Leu Arg Thr Asp Leu Pro Leu Glu Val Asp Phe  
 245 250 255  
 Ala Lys Arg Arg Glu Pro Asp Trp Glu Gly Leu Lys Ala Phe Leu Glu  
 260 265 270  
 Arg Leu Glu Phe Gly Ser Leu Leu His Glu Phe Gly Leu Leu Glu  
 275 280 285

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 287 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Met Leu Pro Leu Leu Glu Pro Lys Gly Arg Val Leu Leu Val Asp Gly  
 1 5 10 15  
 His His Leu Ala Tyr Arg Thr Phe Phe Ala Leu Lys Gly Leu Thr Thr  
 20 25 30  
 Ser Arg Gly Glu Pro Val Gln Ala Val Tyr Gly Phe Ala Lys Ser Leu  
 35 40 45  
 Leu Lys Ala Leu Lys Glu Asp Gly Glu Val Ala Ile Val Val Phe Asp  
 50 55 60  
 Ala Lys Ala Pro Ser Phe Arg His Glu Ala Tyr Glu Ala Tyr Lys Ala  
 65 70 75 80  
 Gly Arg Ala Pro Thr Pro Glu Asp Phe Pro Arg Gln Leu Ala Leu Ile  
 85 90 95  
 Lys Glu Leu Val Asp Leu Leu Gly Leu Val Arg Leu Glu Val Pro Gly  
 100 105 110  
 Phe Glu Ala Asp Asp Val Leu Ala Thr Leu Ala Arg Lys Ala Glu Arg  
 115 120 125  
 Glu Gly Tyr Glu Val Arg Ile Leu Ser Ala Asp Arg Asp Leu Tyr Gln  
 130 135 140  
 Leu Leu Ser Asp Arg Ile His Leu Leu His Pro Glu Gly Glu Val Leu  
 145 150 155 160  
 Thr Pro Gly Trp Leu Gln Glu Arg Tyr Gly Leu Ser Pro Glu Arg Trp  
 165 170 175

55

Val Glu Tyr Arg Ala Leu Val Gly Asp Pro Ser Asp Asn Leu Pro Gly  
 180 185 190  
 Val Pro Gly Ile Gly Glu Lys Thr Ala Leu Lys Leu Lys Glu Trp  
 195 200 205  
 Gly Ser Leu Glu Ala Ile Leu Lys Asn Leu Asp Gln Val Lys Pro Glu  
 210 215 220  
 Arg Val Trp Glu Ala Ile Arg Asn Asn Leu Asp Lys Leu Gln Met Ser  
 225 230 235 240  
 Leu Glu Leu Ser Arg Leu Arg Thr Asp Leu Pro Leu Glu Val Asp Phe  
 245 250 255  
 Ala Lys Arg Arg Glu Pro Asp Trp Glu Gly Leu Lys Ala Phe Leu Glu  
 260 265 270  
 Arg Leu Glu Phe Gly Ser Leu Leu His Glu Phe Gly Leu Leu Glu  
 275 280 285

## (2) INFORMATION FOR SEQ ID NO:9:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2682 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA (genomic)

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

ATGAGAGGCA TGCTTCCACT TTTTGAGGCC AAGGGCCGGG TCCTCCTGGT GGACGGCCAC 60  
 CACCTGGCCT ACCGCACCTT CCACGCCCTG AAGGGCCTCA CCACCAGCCG GGGGAGCCG 120  
 GTGCAGGCGG TCTACGACTT CGCCAAGAGC CTCCTCAAGG CCCTCAAGGA GGACGGGGAC 180  
 GCGGTGATCG TGGTCTTTGA CGCCAAGGCC CCCTCCTTCC GCCACGAGGC CTACGGTGGG 240  
 TACAAGGCGG GCCGGGCCCC CACGCCG3AG GACTTTCCCC GGCAACTCGC CCTCATCAAG 300  
 GAGCTGGTAG ATCTCCTGGG GCTGGCGCGC CTCGAGGTCC CGGGCTACGA GCGGAGCGAC 360  
 GTCTGGCCA GCCTGGCCAA GAAGGCG3AA AAGGAGGGCT ACGAGGTCCG CATCCTCACC 420  
 GCCGACAAAG ACCTTTACCA GCTCCTTTCC GACCGCATCC ACGTCCTCCA CCCCAGGGG 480  
 TACCTCATCA CCCCAGCCTG GCTTTGG3AA AAGTACGGCC TGAGGCCCGA CCAGTGGGCC 540  
 GACTACCGGG CCCTGACCGG GGACGAGTCC GACAACATCC CCGGGGTAC TGGGATCGGT 600  
 GAGAAGACTG CTGTTGAGCT TCTAGAGAAG TACAAAGACC TCGAAGACAT ACTGAATCAT 660  
 GTTCGCGAAC TTCTCAAAA GGTGAGAAAA GCCCTGCTTC GAGACAGAGA AACGCCATT 720  
 CTCAGCAAAA AGCTGGCGAT TCTGGAAACA AACGTTCCCA TTGAAATAAA CTGGGAAGAA 780  
 TTTCGCTACC AGGGCTACGA CAGAGAGAAA CTCTTACCAC TTTTGAAAGA ACTGGAATTC 840  
 GCATCCATCA TGAAGGAACT TCAACTGTAC GAAGAGTCCG AACCCGTGG ATACAGAATA 900  
 GTGAAAGACC TAGTGAATT TGA AAAACTC ATAGAGAAAC TGAGAGAATC CCCTTCGTTC 960  
 GCCATAGATC TTGAGACGTC TTCCCTCGAT CCTTTCGACT GCGACATTGT CGGTATCTCT 1020  
 GTGTCTTTCA AACCAAAGGA AGCGTACTAC ATACCACTCC ATCATAGAAA CGCCGAGAAC 1080

CTGGACGAAA AAGAGGTTCT GAAAAAGCTC AAAGAAATTC TGGAGGACCC CGGAGCAAAG 1140  
 ATCGTTGGTC AGAATTTGAA ATTCGATTAC AAGGTGTTGA TGGTGAAGGG TGTGTAACCT 1200  
 5 GTTCCTCCTT ACTTCGACAC GATGATAGCG GCTTACCTTC TTGAGCCGAA CGAAAAGAAG 1260  
 TTCAATCTGG ACGATCTCGC ATTGAAATTT CTTGGATACA AAATGACATC TTACCAAGAG 1320  
 CTCATGTCTT TCTCTTTTCC GCTGTTTGGT TTCAGTTTGG CCGATGTTCC TGTAGAAAAA 1380  
 10 GCAGCGAACT ACTCCTGTGA AGATGCAGAC ATCACCTACA GACTTTACAA GACCCTGAGC 1440  
 TTAAAACTCC ACGAGGCAGA TCTGAAAAAC GTGTCTTACA AGATAGAAAT GCCCCTTGTG 1500  
 AACGTCCTTG CACGGATGGA ACTGAACGGT GTGTATGTGG ACACAGAGTT CCTGAAGAAA 1560  
 CTCTCAGAAG AGTACGGAAG AAAACTCGAA GAACCTGGCAG AGGAAATATA CAGGATAGCT 1620  
 15 GGAGAGCCGT TCAACATAAA CTCACCGAAG CAGGTTTCAA GGATCCTTTT TGA AAAACTC 1680  
 GGCATAAAAC CACGTGGTAA AACGACGAAA ACGGGAGACT ATTCAACACG CATAGAAGTC 1740  
 CTCGAGGAAC TTGCCCGTGA ACACGAAATC ATTCCTCTGA TTCTTGAATA CAGAAAGATA 1800  
 CAGAAATGTA AATCAACCTA CATAGACGCT CTTCCCAAGA TGGTCAACCC AAAGACCGGA 1860  
 20 AGGATTTCATG CTTTCTTCAA TCAAACGGGG ACTGCCACTG GAAGACTTAG CAGCAGCGAT 1920  
 CCCAATCTTC AGAACCTCCC GACGAAAAGT GAAGAGGGAA AAGAAATCAG GAAAGCGATA 1980  
 GTTCCTCAGG ATCCAAACTG GTGGATCGTC AGTGCCGACT ACTCCCAAT AGAACTGAGG 2040  
 25 ATCCTCGCCC ATCTCAGTGG TGATGAGAAT CTTTGTAGGG CATTGGAAGA GGGCATCGAC 2100  
 GTCCACACTC TAACAGCTTC CAGAATATTC AACGTGAAAC CCGAAGAAGT AACCGAAGAA 2160  
 ATGCGCCGCG CTGGTAAAT GGTAAATTTT TCCATCATAT ACGGTGTAAC ACCTTACGGT 2220  
 CTGTCTGTGA GGCTTGGAGT ACCTGTGAAA GAAGCAGAAA AGATGATCGT CAACTACTTC 2280  
 30 GTCCTCTACC CAAAGGTGCG CGATTACATT CAGAGGGTCG TATCGGAAGC GAAAGAAAAA 2340  
 GGCTATGTTA GAACGCTGTT TGAAGAAAAA AGAGACATAC CACAGCTCAT GGCCCGGGAC 2400  
 AGGAACACAC AGGCTGAAGG AGAACGAATT GCCATAACA CTCCCATACA GGTACAGCA 2460  
 35 GCGGATATAA TAAAGCTGGC TATGATAGAA ATAGACAAGG AACTGAAAGA AAGAAAAATG 2520  
 AGATCGAAGA TGATCATACA GGTCCACGAC GAACTGGITT TTGAAGTGCC CAATGAGGAA 2580  
 AAGGACGCGC TCGTCGAGCT GGTGAAAGAC AGAATGACGA ATGTGGTAAA GCTTTCAGTG 2640  
 40 CCGCTCGAAG TGGATGTAAC CATCGGCAAA ACATGGTCGT GA 2682

## (2) INFORMATION FOR SEQ ID NO:10:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 893 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Met Ala Arg Leu Phe Leu Phe Asp Gly Thr Ala Leu Ala Tyr Arg Ala  
 1 5 10 15

EP 0 892 058 A2

Tyr Tyr Ala Leu Asp Arg Ser Leu Ser Thr Ser Thr Gly Ile Pro Thr  
 20 25 30  
 5 Asn Ala Thr Tyr Gly Val Ala Arg Met Leu Val Arg Phe Ile Lys Asp  
 35 40 45  
 His Ile Ile Val Gly Lys Asp Tyr Val Ala Val Ala Phe Asp Lys Lys  
 50 55 60  
 10 Ala Ala Thr Phe Arg His Lys Leu Leu Glu Thr Tyr Lys Ala Gln Arg  
 65 70 75 80  
 Pro Lys Thr Pro Asp Leu Leu Ile Gln Gln Leu Pro Tyr Ile Lys Lys  
 85 90 95  
 Leu Val Glu Ala Leu Gly Met Lys Val Leu Glu Val Glu Gly Tyr Glu  
 100 105 110  
 15 Ala Asp Asp Ile Ile Ala Thr Leu Ala Val Lys Gly Leu Pro Leu Phe  
 115 120 125  
 Asp Glu Ile Phe Ile Val Thr Gly Asp Lys Asp Met Leu Gln Leu Val  
 130 135 140  
 20 Asn Glu Lys Ile Lys Val Trp Arg Ile Val Lys Gly Ile Ser Asp Leu  
 145 150 155 160  
 Glu Leu Tyr Asp Ala Gln Lys Val Lys Glu Lys Tyr Gly Val Glu Pro  
 165 170 175  
 25 Gln Gln Ile Pro Asp Leu Leu Ala Leu Thr Gly Asp Glu Ile Asp Asn  
 180 185 190  
 Ile Pro Gly Val Thr Gly Ile Gly Glu Lys Thr Ala Val Gln Leu Leu  
 195 200 205  
 Glu Lys Tyr Lys Asp Leu Glu Asp Ile Leu Asn His Val Arg Glu Leu  
 210 215 220  
 30 Pro Gln Lys Val Arg Lys Ala Leu Leu Arg Asp Arg Glu Asn Ala Ile  
 225 230 235 240  
 Leu Ser Lys Lys Leu Ala Ile Leu Glu Thr Asn Val Pro Ile Glu Ile  
 245 250 255  
 35 Asn Trp Glu Glu Leu Arg Tyr Gln Gly Tyr Asp Arg Glu Lys Leu Leu  
 260 265 270  
 Pro Leu Leu Lys Glu Leu Glu Phe Ala Ser Ile Met Lys Glu Leu Gln  
 275 280 285  
 40 Leu Tyr Glu Glu Ser Glu Pro Val Gly Tyr Arg Ile Val Lys Asp Leu  
 290 295 300  
 Val Glu Phe Glu Lys Leu Ile Glu Lys Leu Arg Glu Ser Pro Ser Phe  
 305 310 315 320  
 Ala Ile Asp Leu Glu Thr Ser Ser Leu Asp Pro Phe Asp Cys Asp Ile  
 325 330 335  
 45 Val Gly Ile Ser Val Ser Phe Lys Pro Lys Glu Ala Tyr Tyr Ile Pro  
 340 345 350  
 Leu His His Arg Asn Ala Gln Asn Leu Asp Glu Lys Glu Val Leu Lys  
 355 360 365  
 50 Lys Leu Lys Glu Ile Leu Glu Asp Pro Gly Ala Lys Ile Val Gly Gln  
 370 375 380  
 Asn Leu Lys Phe Asp Tyr Lys Val Leu Met Val Lys Gly Val Glu Pro  
 385 390 395 400  
 55

Val Pro Pro Tyr Phe Asp Thr Met Ile Ala Ala Tyr Leu Leu Glu Pro  
 405 410 415  
 Asn Glu Lys Lys Phe Asn Leu Asp Asp Leu Ala Leu Lys Phe Leu Gly  
 420 425 430  
 Tyr Lys Met Thr Ser Tyr Gln Glu Leu Met Ser Phe Ser Phe Pro Leu  
 435 440 445  
 Phe Gly Phe Ser Phe Ala Asp Val Pro Val Glu Lys Ala Ala Asn Tyr  
 450 455 460  
 Ser Cys Glu Asp Ala Asp Ile Thr Tyr Arg Leu Tyr Lys Thr Leu Ser  
 465 470 475 480  
 Leu Lys Leu His Glu Ala Asp Leu Glu Asn Val Phe Tyr Lys Ile Glu  
 485 490 495  
 Met Pro Leu Val Asn Val Leu Ala Arg Met Glu Leu Asn Gly Val Tyr  
 500 505 510  
 Val Asp Thr Glu Phe Leu Lys Lys Leu Ser Glu Glu Tyr Gly Lys Lys  
 515 520 525  
 Leu Glu Glu Leu Ala Glu Glu Ile Tyr Arg Ile Ala Gly Glu Pro Phe  
 530 535 540  
 Asn Ile Asn Ser Pro Lys Gln Val Ser Arg Ile Leu Phe Glu Lys Leu  
 545 550 555 560  
 Gly Ile Lys Pro Arg Gly Lys Thr Thr Lys Thr Gly Asp Tyr Ser Thr  
 565 570 575  
 Arg Ile Glu Val Leu Glu Glu Leu Ala Gly Glu His Glu Ile Ile Pro  
 580 585 590  
 Leu Ile Leu Glu Tyr Arg Lys Ile Gln Lys Leu Lys Ser Thr Tyr Ile  
 595 600 605  
 Asp Ala Leu Pro Lys Met Val Asn Pro Lys Thr Gly Arg Ile His Ala  
 610 615 620  
 Ser Phe Asn Gln Thr Gly Thr Ala Thr Gly Arg Leu Ser Ser Ser Asp  
 625 630 635 640  
 Pro Asn Leu Gln Asn Leu Pro Thr Lys Ser Glu Glu Gly Lys Glu Ile  
 645 650 655  
 Arg Lys Ala Ile Val Pro Gln Asp Pro Asn Trp Trp Ile Val Ser Ala  
 660 665 670  
 Asp Tyr Ser Gln Ile Glu Leu Arg Ile Leu Ala His Leu Ser Gly Asp  
 675 680 685  
 Glu Asn Leu Leu Arg Ala Phe Glu Glu Gly Ile Asp Val His Thr Leu  
 690 695 700  
 Thr Ala Ser Arg Ile Phe Asn Val Lys Pro Glu Glu Val Thr Glu Glu  
 705 710 715 720  
 Met Arg Arg Ala Gly Lys Met Val Asn Phe Ser Ile Ile Tyr Gly Val  
 725 730 735  
 Thr Pro Tyr Gly Leu Ser Val Arg Leu Gly Val Pro Val Lys Glu Ala  
 740 745 750  
 Glu Lys Met Ile Val Asn Tyr Phe Val Leu Tyr Pro Lys Val Arg Asp  
 755 760 765  
 Tyr Ile Gln Arg Val Val Ser Glu Ala Lys Glu Lys Gly Tyr Val Arg  
 770 775 780

Thr Leu Phe Gly Arg Lys Arg Asp Ile Pro Gln Leu Met Ala Arg Asp  
 785 790 795 800  
 5 Arg Asn Thr Gln Ala Glu Gly Glu Arg Ile Ala Ile Asn Thr Pro Ile  
 805 810 815  
 Gln Gly Thr Ala Ala Asp Ile Ile Lys Leu Ala Met Ile Glu Ile Asp  
 820 825 830  
 10 Arg Glu Leu Lys Glu Arg Lys Met Arg Ser Lys Met Ile Ile Gln Val  
 835 840 845  
 His Asp Glu Leu Val Phe Glu Val Pro Asn Glu Glu Lys Asp Ala Leu  
 850 855 860  
 15 Val Glu Leu Val Lys Asp Arg Met Thr Asn Val Val Lys Leu Ser Val  
 865 870 875 880  
 Pro Leu Glu Val Asp Val Thr Ile Gly Lys Thr Trp Ser  
 885 890

(2) INFORMATION FOR SEQ ID NO:11:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 30 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

GGGAAGGGCG ATCGGTGCGG GCCTCTTCGC

30

### Claims

1. A thermostable DNA polymerase consisting of an N-terminal region and a C-terminal region, wherein said N-terminal region consists of amino acids 1 through n of a *Thermus* species DNA polymerase, wherein n is an amino acid corresponding to an amino acid m of *Thermatoga maritima* (*Tma*) DNA polymerase, SEQ ID NO: 10, wherein m is between 137 and 291;

wherein said C-terminal region consists of amino acids m+1 through 893 of *Tma* DNA polymerase, SEQ ID NO: 10;

wherein said N-terminal region is modified by at least one point mutation that substantially reduces or eliminates 5'-nuclease activity when present in said *Thermus* species DNA polymerase, or said C-terminal region is modified by at least one point mutation within the region that is amino acids m+1 to 291 of *Tma* DNA polymerase that substantially reduces or eliminates 5'-nuclease activity when present in *Tma* DNA polymerase;

wherein said C-terminal region is modified by at least one point mutation that substantially reduces 3' to 5' exonuclease activity when present in *Tma* DNA polymerase; and

wherein said C-terminal region is modified to contain a tyrosine at amino acid 730.

2. The thermostable DNA polymerase of Claim 1, wherein said N-terminal region contains a point mutation at an amino acid position corresponding to an amino acid in *Taq* DNA polymerase selected from the group consisting of D18, R25, G46, D67, F73, R74, Y81, G107, E117, D119, D120, D142, D144, G187, D188, D191, and G195.

3. The thermostable DNA polymerase of Claim 1, wherein said C-terminal region contains a point mutation at an amino acid position selected from the group consisting of D323, E325, L329, N385, D389, L393, Y464, and D468.
4. The thermostable DNA polymerase of Claim 2, wherein said N-terminal region contains an aspartic acid at an amino acid position corresponding to amino acid G46 in *Taq* DNA polymerase.
5. The thermostable DNA polymerase of Claim 3, wherein said C-terminal region contains a D323A or E325A mutation.
6. The thermostable DNA polymerase of Claim 1, wherein said *Thermus* species is selected from the group consisting of *Thermus aquaticus*, *Thermus flavus*, *Thermus thermophilus*, *Thermus species Z05*, *Thermus caldofilus*, *Thermus species sps17*, *Thermus filiformis*.
7. The thermostable DNA polymerase of Claim 6, wherein said *Thermus* species is *Thermus aquaticus*.
8. The thermostable DNA polymerase of Claim 7, wherein  $n = 190$ .
9. The thermostable DNA polymerase of Claim 8, wherein said N-terminal region contains an G46D mutation, and wherein said C-terminal region contains a D323A mutation and a E325A mutation.
10. An isolated DNA that encodes a thermostable DNA polymerase as claimed in any one of claims 1 to 9.
11. A plasmid comprising a DNA that encodes a thermostable DNA polymerase as claimed in any one of claims 1 to 9.
12. An expression vector comprising a DNA that encodes a thermostable DNA polymerase as claimed in any one of claims 1 to 9.
13. A host cell transformed with an expression vector comprising a DNA that encodes a thermostable DNA polymerase as claimed in any one of claims 1 to 9.
14. A method for preparing a thermostable DNA polymerase, comprising:
  - (a) culturing a host cell transformed with an expression vector comprising a DNA that encodes a thermostable DNA polymerase as claimed in any one of claims 1 to 9 under conditions which promote the expression of thermostable DNA polymerase; and
  - (b) isolating thermostable DNA polymerase from said host cell.
15. A thermostable DNA polymerase prepared by the method as claimed in claim 14.
16. A method for sequencing a nucleic acid wherein a thermostable DNA polymerase as claimed in any one of claims 1 to 9 or 15 is used.
17. Use of a thermostable DNA polymerase as claimed in any one of claims 1 to 9 or 15 in a nucleic acid amplification or sequencing reaction.
18. A composition comprising a thermostable DNA polymerase as claimed in any one of claims 1 to 9 or 15 and one or more non-ionic polymeric detergents.
19. A kit for carrying out a primer extension reaction, comprising thermostable DNA polymerase as claimed in any one of claims 1 to 9 or 15.

Tma	=	<i>Thermatoga maritima</i>	(SEQ ID NO: 1)
Taq	=	<i>Thermus aquaticus</i>	(SEQ ID NO: 2)
Tfl	=	<i>Thermus flavus</i>	(SEQ ID NO: 3)
Tth	=	<i>Thermus thermophilus</i>	(SEQ ID NO: 4)
T205	=	<i>Thermus species Z05</i>	(SEQ ID NO: 5)
Tca	=	<i>Thermus caldofilus</i>	(SEQ ID NO: 6)
Tsps17	=	<i>Thermus species sps17</i>	(SEQ ID NO: 7)
Tfi	=	<i>Thermus filiformus</i>	(SEQ ID NO: 8)

<i>Tua</i>	.....	MARLFI,FDGTA	LAYRAY	YALDRSL	STSTGI	P	TNATYGV	ARMLVR	FIKDHJ	50		
<i>Taq</i>	MRGMLPL	FEKGRV	LLVDGH	HLAYRT	FIAL		KGLTTSR	GEVPQ	AVYGF	AKSLIK	57	
<i>Tfl</i>	MAMLPL	FEKGRV	LLVDGH	HLAYRT	FFAL		KGLTTSR	GEVPQ	AVYGF	AKSLIK	56	
<i>Tth</i>	MEAMLPL	FEKGRV	LLVDGH	HLAYRT	FFAL		KGLTTSR	GEVPQ	AVYGF	AKSLIK	57	
<i>TZ05</i>	MKAMLPL	FEKGRV	LLVDGH	HLAYRT	FFAL		KGLTTSR	GEVPQ	AVYGF	AKSLIK	57	
<i>Tca</i>	MEAMLPL	FEKGRV	LLVDGH	HLAYRT	FFAL		KGLTTSR	GEVPQ	AVYGF	AKSLIK	57	
<i>Tsps17</i>	...MLPL	FEKGRV	LLVDGH	HLAYRT	FFAL		KGLTTSR	GEVPQ	AVYGF	AKSLIK	54	
<i>Tfi</i>	...MLPL	LEKGRV	LLVDGH	HLAYRT	FFAL		KGLTTSR	GEVPQ	AVYGF	AKSLIK	54	
<i>Tua</i>	IVGK	..DYVA	VFDA	KAA	TFRHKL	LE	TYKA	QRKP	TPDLL	IQQLPY	IKKLVEAL	110
<i>Taq</i>	..DG	..DAVI	VVDA	KAP	SFRH	EAYG	GYKA	GRAP	TPPED	FPQLAL	IKELVDL	115
<i>Tfl</i>	..DG	..DVVV	VVDA	KAP	SFRH	EAYE	AYKA	GRAP	TPPED	FPQLAL	IKELVDL	114
<i>Tth</i>	..DGYK	AVFV	VVDA	KAP	SFRH	EAYE	AYKA	GRAP	TPPED	FPQLAL	IKELVDL	116
<i>TZ05</i>	..DGYK	AVFV	VVDA	KAP	SFRH	EAYE	AYKA	GRAP	TPPED	FPQLAL	IKELVDL	116
<i>Tca</i>	..DGYK	AVFV	VVDA	KAP	SFRH	EAYE	AYKA	GRAP	TPPED	FPQLAL	IKELVDL	116
<i>Tsps17</i>	..DGEVAI	..VVDA	KAP	SFRH	EAYE	AYKA	GRAP	TPPED	FPQLAL	IKELVDL	IKELVLR	112
<i>Tfi</i>	..DGEVAI	..VVDA	KAP	SFRH	EAYE	AYKA	GRAP	TPPED	FPQLAL	IKELVDL	IKELVLR	112



FIGURE 1B

	* * *				
<i>Tma</i>	YEADDIATLAVKGLPLFDEIFIVTGDKMDLQVLVNEKIKVWRIVKGISDLELYDAQVKE	170			
<i>Taq</i>	YEADDVLASLAKKAKEGYEVRIITADKDYQLLSDRITHLII . . . . PEGYLITPAWLWE	170			
<i>Tfl</i>	FEADDVLATLAKKAKEGYEVRIITADRDLYQLLSERIAILII . . . . PEGYLITPAWLVE	169			
<i>Tth</i>	YEADDVLATLAKKAKEGYEVRIITADRDLYQLVSDRVAVLII . . . . PEGHILITPEWLWE	171			
<i>T205</i>	FEADDVLATLAKKAEREYEVRIITADRDLYQLVSDRVAVLII . . . . PEGHILITPEWLWE	171			
<i>Tca</i>	YEADDVLATLAKNPEKEGYEVRIITADRDLYQLVSDRVAVLII . . . . PEGHILITPEWLWQ	171			
<i>Tsps17</i>	FEADDVLATLAKKAEREYEVRIISADRDLYQLLSDRITHLII . . . . PEGEVLITPGWLQE	167			
<i>Tfi</i>	FEADDVLATLAKKAEREYEVRIISADRDLYQLLSDRITHLII . . . . PEGEVLITPGWLQE	167			
	* * *				
<i>Tma</i>	KYGVPEQQIPDLLALTGDEIDNIPGVGTIGECTAVQLLEKYKDLED'INIVREL'PQ.KVRK	230			
<i>Taq</i>	KYGLRPDQWADYRALTGDESDNLPGVKGIGECTARKLLEWGSLEALLKNLDRI.KP.AIRE	230			
<i>Tfl</i>	KYGLRPEQWVDYRALAGDPSDNIPGVKGIGECTAQRILIREWGSLENLFQILDQVKP.SLRE	229			
<i>Tth</i>	KYGLRPEQWVDYRALVGDPSDNLPGVKGIGECTALKLLKEWGSLENLLKNLDRVKPENVRE	232			
<i>T205</i>	KYGLKPEQWVDYRALVGDPSDNLPGVKGIGECTALKLLKEWGSLENLLKNLDRVKPENVRE	232			
<i>Tca</i>	KYGLKPEQWVDYRALVGDPSDNLPGVKGIGECTALKLLKEWGSLENLLKNLDRVKPENVRE	232			
<i>Tsps17</i>	RYGLSPERWVEYRALVGDPSDNLPGVPGIGECTALKLLKEWGSLEAFLKNLDQVKPERVRE	228			
<i>Tfi</i>	RYGLSPERWVEYRALVGDPSDNLPGVPGIGECTALKLLKEWGSLEAFLKNLDQVKPERVRE	228			
	* * *				
<i>Tma</i>	ALLRDRENAILSKKLAILETNVPIEINWELRYQGYDREKLLPLLLKELEFASIMKELQLYE	291			
<i>Taq</i>	KILAHMDDLKLSWDLAKVRTDLPLEVDFAKRRREP . . DRERIRAFLEERLEFGSLLHEFGGLE	289			
<i>Tfl</i>	KLQAGMEALALSRKLSQVHTDLPLEVDFFGRRRTP . . NLEGLRAFLEERLEFGSLLHEFGGLE	288			
<i>Tth</i>	KIKAHLEDLRLSLELSRVRTDLPLEVDLAQGREP . . DREGLRAFLEERLEFGSLLHEFGGLE	291			
<i>T205</i>	RIKAHLEDLRLSLELSRVSDLPLEVDFARRREP . . DREGLRAFLEERLEFGSLLHEFGGLE	291			
<i>Tca</i>	KIKAHLEDLRLSLELSRVRTDLPLEVDLAQGREP . . DREGLRAFLEERLEFGSLLHEFGGLE	291			
<i>Tsps17</i>	AIRNNLDKLQMSLELSRLRTDLPLEVDFAKRRREP . . DWEGIKAFLEERLEFGSLLHEFGGLE	287			
<i>Tfi</i>	AIRNNLDKLQMSLELSRLRTDLPLEVDFAKRRREP . . DWEGIKAFLEERLEFGSLLHEFGGLE	287			

FIGURE 2A




FIGURE 2B




FIGURE 2C




FIGURE 3A




FIGURE 3B




FIGURE 3C

